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1. Introduction 
1.1 Cancer 
 
Cancer is the second leading cause of death in the Western world. The four cancer 
types that are responsible for the largest number of deaths worldwide are lung, liver, 
stomach and colon, whereas in developed countries, breast, prostate and pancreas 
carcinoma are a major concern [1, 2].  
 
1.1.1 Cancer biology  
 
Carcinogenesis develops in a multistep process. Malignant tumors are characterized 
by fast proliferation and the ability to migrate and invade to other tissues. Hanahan and 
Weinberg defined the hallmarks of cancer describing the capabilities a cell must 
acquire to undergo the multistep development of tumors. These hallmarks include: 
advantages in the proliferative behavior of tumor cells, evading growth suppressors 
and eluding apoptosis, enabling replicative immortality, fostering angiogenesis, 
enhancing the ability of the tumor to invade and metastasize into other tissues and 
organs as well as escaping the immune system and deregulating cellular energetics 
[3]. In addition to these hallmarks, two consequential characteristics were defined: 
genome instability and mutation, and tumor-promoting inflammation [3].  
The resulting tumor mass consists not only of tumor cells, but is also comprised by a 
variety of normal cells, such as fibroblasts and myofibroblasts, pericytes, epithelial, 
vascular and immune cells, secreted factors and the extracellular matrix (ECM), which 
interact with the malignant cells, and are collectively referred to as the tumor stroma 
[4-6]. Over the last few years, the tumor stroma has emerged as an important target 
for the development of innovative anticancer strategies. The stroma forms a complex 
network of signaling and crosstalk between tumor and the tumor-associated cells that 
help drive cell progression, apoptosis and migration. Various inflammatory cytokines, 
growth factors and chemokines are key molecules for regulating these cell-cell 
interactions and are secreted by both the tumor cells and normal cells within the tumor 
microenvironment. Important factors in this context include the pleiotropic transforming 
growth factor beta (TGFB), fibroblast growth factor 2 (FGF2) and platelet-derived 
growth factor (PDGF), which can activate carcinoma-associated fibroblasts (CAFs) as 
well as foster angiogenesis [7].  
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Fig. 1: Schematic illustration of the tumor stroma consisting of tumor cells, cancer-associated fibroblasts 
(CAFs), immune cells, vascular endothelial cells and pericytes. All these components interact with the 
tumor cells and influence tumor growth, progression and angiogenesis (based on Balkwill et al. [8]).  
 
CAFs originate from local fibroblasts or progenitor cells such as epithelial cells, smooth 
muscle cells or mesenchymal stem cells [8]. CAFs play different roles within the tumor 
microenvironment, they can have a mitogenic effect on tumor cells by secreting growth 
factors such as the hepatocyte growth factor (HGF) or FGF, influence the epithelial-
mesenchymal transition (EMT) by secreting TGFB or promote tumor growth due to 
stromal cell-derived factor 1 (SDF-1) or insulin-like growth factor-1 and -2 secretion [8-
10].  
An important step in tumorigenesis is the development of new blood vessels, called 
angiogenesis. A central player in tumor angiogenesis is the vascular endothelial growth 
factor (VEGF), which is released within the tumor environment as a response to 
different signals, including hypoxia that helps to induce neovascularization as well as 
microvascular permeability [7]. Endothelial cells then build blood vessels, which are 
supported by pericytes to supply the tumor with oxygen and nutrients. The blood 
vessels of the tumor are heterogenous and differ in their function as compared to 
normal blood vessels [8]. They are characterized by a leaky structure allowing 
molecules to travel between the blood capillaries and interstitial space.  
Another important component of the tumor stroma are immune cells, which include: B- 
and T-lymphocytes, neutrophils, neutral killer (NK) and NKT-cells, dendritic cells and 
tumor-associated macrophages (TAM). These cells are described to have either a 
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promoting or inhibiting effect on tumor progression, depending on the tumor type and 
stage of the disease or polarization of the macrophages [8]. TAMs for example express 
antitumorigenic proteins but also promote tumorigenesis by producing various growth 
factors (HGF, VEGF and TGFB) or cytokines (tumor necrosis factor alpha (TNFα) and 
interleukin 8 (IL8)).  
Although the tumor stroma is in general composed of the same elements, the amount 
of stroma varies among different tumor types [4]. Breast, stomach or pancreatic 
carcinomas are described as desmoplastic carcinomas, where the tumor stroma 
constitutes about 90 % of the tumor, whereas other cancer types possess only a small 
stromal compartment [4]. The microenvironment of the tumor is critical for tumor growth 
and spread and represents a complex and heterogeneous tissue. The biology behind 
carcinogenesis and its complexities regarding genomic changes, cell signaling, the role 
of the tumor stroma as well as intra- and interheterogeneity of tumors, has opened new 
avenues for novel therapeutic approaches.  
 
1.1.2 Anticancer therapy 
 
Traditional anticancer therapies include surgery, chemotherapy and radiotherapy. 
Surgery, when possible, is considered the most effective technique to eliminate solid 
tumors. Nearly half of all cancer patients receive radiotherapy as the initial treatment 
in early stage head and neck tumors, prostate cancer or as adjunct treatment to 
surgery or chemotherapy [11]. Cytotoxic chemotherapy uses agents that interfere with 
the process of cell growth. However, chemotherapy is usually associated with 
significant systemic toxicity [12]. Although these traditional anticancer therapies can 
be effective, many cancer patients still suffer from negative side effects and poor 
prognosis due to relapse or metastasis. Due to a better understanding of the biology 
of carcinogenesis, various novel therapy strategies have been developed or are 
currently under investigation.  
Targeted therapy is based on the biological characteristics of the tumor. The 
expression patterns of receptors for growth factors or hormones or deregulated 
signaling pathways can be used to directly target cancer cells or the tumor 
microenvironment. To date, various therapies have been developed which directly 
target molecular structures such as receptors, inhibit signal transduction, modulate 
gene expression, induce apoptosis, inhibit angiogenesis or trigger the immune system 
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[11, 13]. In the last few decades, great progress has been made in the development of 
targeted cancer gene therapy. Gene therapy, or gene transfer, is a method used to 
introduce genetic material into cells to act locally as therapeutic agents. Principles of 
gene therapy are [14]:  
 
 Gene re-expression 
A vector is used to restore gene expression by delivering the functioning version of 
a mutant gene into the tumor cell.  
 
 Suicide genes 
A non-toxic prodrug is administered in combination with the tumor-specific delivery 
of the prodrug-activating gene. The tumor cell then transforms the prodrug into a 
toxic metabolite, leading to apoptosis.  
 
 Immunotherapy 
To stimulate immune response against tumor cells, genes for specific immunogenic 
tumor antigens, co-stimulatory molecules or inflammatory cytokines are carried to 
tumor cells by a vector. 
 
 Oncolytic viruses 
Oncolytic viruses specifically replicate in tumor cells and are characterized by tumor 
cell-specific toxicity. 
 
 Therapeutic RNA interference 
Synthetic double-stranded short interfering RNA (siRNA) or short hairpin (shRNA) 
(expressed by a vector) bind an oncogene RNA resulting in inhibition of the 
oncogene translation or RNA cleavage and thus in cell apoptosis. 
 
To date, most gene therapy approaches are focused on vehicle administration for local 
gene delivery to reach sufficient transgene expression in tumors. However, metastatic 
disease requires systemic vector application to reach not only the primary tumor but 
also tumor metastases throughout the body. Success and effectiveness of these gene 
therapy strategies rely on the choice of the vector, especially if systemic delivery is the 
goal. The genetic material must be sufficiently protected against degradation before it 
is released selectively in the tumor cells. To date, various viral and non-viral vectors 
are available to deliver therapeutic genes to cancer cells or their environment.  
Recombinant viruses such as adenoviruses, retroviruses, lentiviruses or measles 
viruses have shown to be efficient therapeutic transgene delivery systems to 
  Introduction 
 
5 
 
carcinomas. Replication incompetent adenoviruses have been used to deliver the 
herpes simplex virus thymidine kinase (HSV-TK) gene to tumors to induce tumor cell 
death upon treatment with the prodrug ganciclovir [15]. This method is currently being 
used in experimental trials for cancer treatment and in clinical treatment of brain tumors 
[16]. Limiting factors for viral vectors is their immunogenicity as well as the possibility 
of insertional mutagenesis [14]. In addition to viral systems, non-viral gene transfer 
methods have been extensively investigated to circumvent safety issues of viral 
vectors. Synthetic vectors, such as polymers (polyplexes after DNA complexation), 
cationic liposomes (lipoplexes after DNA complexation) or peptides, have been 
successfully used to deliver DNA to tumor cells [17]. Nanoparticles as vectors 
(lipoplexes or polyplexes) can extravasate through gaps between endothelial cells of 
the blood vessels and accumulate in the tumors due to the enhanced permeability and 
retention (EPR) effect [14].  
Another class of gene delivery vehicles are biological non-viral vectors, such as 
transgene-expressing bacteria or genetically engineered mesenchymal stem cells 
(MSCs), which naturally target tumors. In addition to a suitable vector system for 
therapeutic transgene delivery, the therapeutic gene itself plays a crucial role in the 
effectiveness of an anticancer therapy. One highly promising candidate gene for 
cancer gene therapy combines diagnostic and therapeutic properties: the sodium 
iodide symporter (NIS).  
 
1.2 The sodium iodide symporter (NIS)  
 
1.2.1 General characteristics  
 
The transmembrane glycoprotein NIS consists of 643 amino acids and actively 
transports iodide from the blood stream into thyroid follicular cells (Fig.2). One iodide 
(I-) is transported across the basolateral membrane in exchange for two sodium ions 
(Na+). The sodium gradient that drives the co-transport of Na+ and I- ions is generated 
by a 3 Na+/2 K+ adenosine triphosphatase (ATPase).  
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Fig. 2: Protein structure of the transmembrane human sodium iodide symporter (NIS) (left) and 
schematic illustration of the iodide uptake in a thyroid follicular cell and the processes of thyroid hormone 
synthesis (right). Adapted from Spitzweg et al., J Clin Endocrinol Metab, 2001. 
 
In addition to iodide transport, the NIS protein is also capable of transporting other ions 
such as thiocyanate (SCN-), nitrate (NO3-), bromide (Br-), chlorate (ClO3-), 
tetrafluoborate (BF4-) among others, although with less affinity [18]. A well-known 
competitive NIS-inhibitor is perchlorate (ClO4-).   
Iodide is an essential constituent of thyroid hormones. The process of oxidization of 
iodide to iodine followed by incorporation into thyroglobulin (TG) within the process of 
thyroid hormone synthesis is known as iodide organification. TG is a precursor protein 
of the thyroid hormones T3 (3,5,3′-triiodo-L-thyronine) and T4 (3,5,3′,5′-tetraiodo-L-
thyronine or thyroxine), whose release into the blood stream is regulated by the thyroid-
stimulating hormone (TSH) [19]. Endogenous NIS expression is also present in the 
stomach, salivary glands and lactating mammary glands, but is not regulated by TSH 
and is expressed at lower levels compared to the thyroid gland [20]. 
 
1.2.2 NIS as reporter and therapy gene  
 
The ability of NIS to concentrate iodide in thyroid follicular cells offers the possibility to 
use NIS for molecular imaging and therapy after application of radionuclides. NIS as a 
reporter gene has been used in different approaches for radionuclide imaging of thyroid 
carcinomas and metastases using scintigraphy, single photon emission computed 
tomography (SPECT) (123I, 99mTc or 125I) or  positron emission tomography (PET) 
imaging (124I or 18F-TFB) [21]. Radionuclide imaging allows the diagnosis of thyroid 
cancer patients, the tracking of tumor progression and the detection of metastases. 
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Imaging of tumoral radionuclide accumulation is used to calculate the tumor-absorbed 
dose prior to a therapeutic application of radionuclides. These calculations allow a 
personalized adjustment of the applied radionuclide dose (131I, 188Re, 211At) with a 
maximal therapeutic effect and minimal toxicity [20-23]. The therapeutic effect is 
achieved by ionizing radiation, which kills cells by breaking DNA and disrupting cellular 
proteins. In addition, NIS-mediated radioiodide therapy is characterized by a bystander 
effect resulting from the crossfire effect of the beta-emitter radionuclide 131I. These 
effects lead to apoptosis of the neighboring cells. Further, the therapeutic radioiodine 
is organified in thyroid follicular cancer cells, which leads to a prolonged retention time 
of tumoral iodine resulting in a high tumor-absorbed dose of 131I. The successful and 
effective radioiodine therapy makes NIS an interesting and promising candidate to 
develop a cytoreductive gene therapy strategy based on NIS transgene delivery to 
non-thyroidal tumors.   
 
1.2.3 NIS gene therapy 
 
An important step in administering NIS for imaging and therapy in non-thyroidal tumors 
was the cloning and characterization of the NIS gene [24]. This breakthrough allowed 
the transfection of non NIS-expressing tumor cells with NIS DNA. Shimura et al. were 
the first to demonstrate the successful delivery of 125I for noninvasive gamma camera 
imaging after transfection of a clonal variant FRLT thyroid cell line with rat NIS [25]. 
The cloning and characterization of NIS and the extensive clinical experience in NIS-
based diagnosis and treatment of thyroid carcinomas effectively set the stage for the 
potential introduction of NIS into nonthyroidal tumors using diverse gene delivery 
vehicles including viral and non-viral approaches. The evaluation of NIS gene transfer 
was performed in a series of preclinical studies that demonstrated effective and 
successful 131I-based therapy in various tumor types including prostate, colon, liver, 
pancreatic and ovarian carcinomas [26].  
The most common vectors used in preclinical and clinical studies are viruses, which 
have been widely investigated for NIS transgene delivery. Pioneering studies of 
Spitzweg et al. used an adenovirus and the cytomegalovirus (CMV) promoter to control 
NIS transgene expression in transfected prostate cancer cells, which was applied 
intratumorally. This study demonstrated for the first time that in vivo NIS gene transfer 
to non-thyroidal tumors resulted in a significant therapeutic effect after radionuclide 
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application [27]. Further studies investigated the potential of specific promoters, such 
as the alpha-fetoprotein (AFP) or a prostate-specific (probasin) promoter to control NIS 
expression after adenovirus-mediated intratumoral delivery in different tumor mouse 
models for a NIS-mediated radioiodide therapy [28-30]. In human hepatocellular 
carcinoma (HCC), Geoffrey Grünwald from the laboratory of Christine Spitzweg 
intratumorally injected a replication-selective adenovirus in which the E1a gene (for 
viral replication) is driven by the alpha-fetoprotein promoter and the NIS gene is 
inserted within the E3 region (thus NIS is only expressed in tumor cells where 
adenoviral replication takes place) (Ad5-E1/AFP-E3/NIS). The combination of targeted 
oncolytic virotherapy with NIS-mediated radionuclide therapy resulted in an additional 
reduction in HCC tumor growth as compared to virotherapy alone [30]. This local gene 
delivery approaches demonstrated effective transgene expression in tumors but is not 
suitable for the treatment of metastatic disease. To date, relatively few studies have 
investigated systemic injection of NIS transgene delivery vehicles. Systemic 
application is limited by tumor-specific transduction efficiency and safety issues. 
Furthermore, the efficiency of NIS gene transfer is dependent on the ability of the 
delivery system to avoid rapid enzymatic degradation of naked NIS DNA in the blood 
and tissue. Thus, it has been necessary to focus on the investigation of potential 
delivery vehicles that allow effective systemic NIS transgene delivery. Initial studies 
using systemic application of gene delivery vehicles demonstrated an enhanced 
oncolytic potency of an oncolytic measles virus carrying the NIS gene in multiple 
myeloma after systemic injection of the virus followed by radioiodine application [31]. 
Goel et al. designed a NIS-expressing oncolytic vesicular stomatitis virus (VSV) for 
systemic application in multiple myeloma [32]. Kathrin Klutz from the laboratory of 
Christine Spitzweg investigated the potential of a replication-deficient adenovirus with 
the NIS gene linked to the tumor-specific AFP-promoter for systemic injection in mice 
with subcutaneous liver carcinoma. Systemic application of the adenoviral vector 
resulted in high specificity and promoter activation in tumors [28]. In collaboration with 
Prof. Dr. Ernst Wagner, Geoffrey Grünwald coated the replication-deficient adenovirus 
in which NIS is under the control of the CMV-promoter (Ad5-CMV/NIS) and the 
replication-selective Ad5-E1/AFP-E3/NIS with poly(amido-amine) dendrimers of the 
fifth generation (PAMAM-G5) to develop a combination of systemic oncolytic 
virotherapy and NIS-induced radioiodine therapy with improved shielding and 
targeting. Intravenous injection of dendrimer-coated Ad5-CMV/NIS resulted in reduced 
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liver toxicity and enhanced transduction efficacy in HCC xenografts [33]. An enhanced 
oncolytic effect was observed using systemically injected dendrimer-coated Ad5-
E1/AFP-E3/NIS, which was further increased by combining this approach with NIS-
mediated radioiodine therapy resulting in a significantly prolonged survival [33]. New 
adenovirus constructs suitable for systemic application were subsequently developed 
to improve tumor-selective targeting of an adenovirus-mediated NIS gene transfer. 
Viruses containing the NIS transgene were coated with PAMAM linked to the peptidic, 
epidermal growth factor receptor (EGFR)-specific ligand GE11 to specifically target 
high EGFR-expressing tumor cells. Specific targeting and shielding of the virus led to 
reduced liver trapping of the virus after systemic application with reduced 
hepatotoxicity and thereby enhanced transduction efficacy of NIS in peripheral tumor 
cells resulting in a strong therapeutic response [34].  
Although viruses demonstrate high transduction efficacy, they are often accompanied 
by potential risks, such as anti-viral immunity or infection of non-target cells causing 
unwanted side-effects during therapy [35]. To improve safety and targeting efficacy, 
synthetic systems such as polymers have been widely investigated and are now seen 
as promising candidates for systemic NIS transgene delivery. In collaboration with 
Prof. Dr. Ernst Wagner, the laboratory of Christine Spitzweg has further investigated 
the potential of a NIS-mediated radioiodide-based therapy in non-thyroidal tumors 
introducing synthetic polymeric vectors. The first generation of vectors were based on 
oligoethylenimine (OEI)-grafted polypropylenimine dendrimers (G2-HD-OEI) 
complexed with NIS DNA (polyplexes) which were tested in mice harboring 
subcutaneous syngeneic neuroblastoma tumors and subcutaneous HCC xenografts. 
In both models the results showed a therapeutically sufficient accumulation of 
radioiodine resulting in a delay of tumor growth [36, 37]. In further studies, Kathrin Klutz 
et al. of the laboratory of Christine Spitzweg used linear polyethlenimine (LPEI)-based 
polymers shielded with polyethylenglycol (PEG) to reduce toxicity of LPEI and prolong 
blood circulation time. In addition, the tumor-specific ligand for EGFR (GE11) was used 
to specifically target tumor cells for enhanced NIS expression in HCC [38]. LPEI-PEG-
GE11/NIS polyplexes were further investigated in clinically more relevant advanced 
mouse models, an engineered mouse model of endogenous pancreatic ductal 
adenocarcinoma (PDAC) and a colon cancer metastasis mouse model, which allowed 
high quality PET imaging of NIS-mediated radioiodine accumulation in tumors followed 
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by effective 131I therapy in both models with reduced tumor growth and prolonged 
survival of animals [39, 40].  
As LPEI-based polyplexes are accompanied by long-term toxicity and show limited 
specificity among other disadvantages, novel sequence-defined polymers are under 
investigation to enhance biocompability, lower immunogenicity and enhance tumor-
selective transduction efficiency. They consist of small and well biocompatible polymer 
backbones with various functional domains, such as cationic (oligoethanoamino) 
amide cores (for nucleic acid binding), protonatable amino acids (to increase the rate 
of endosomal escape due to a buffer function), PEG linkers (for surface shielding) and 
target ligands (for specific cell binding) [41]. These sequence-defined vectors were 
coupled to a cMET-specific ligand and the resulting cMBP2-PEG-Stp/NIS polyplexes 
were used in vivo for tumor-specific NIS transgene delivery in hepatocellular carcinoma 
resulting in an efficient therapeutic response [41].  
These preclinical studies have effectively demonstrated the great potential for image-
guided NIS-mediated radionuclide therapy of non-thyroidal tumors. Non-invasive 
imaging of NIS transgene expression allows the determination of vector biodistribution 
and calculation of radioiodide uptake in every organ and thus offers a safe therapy 
strategy with individual adjustment of the therapeutic dose. The use of NIS as a 
reporter and therapy gene in the context of non-thyroidal tumor gene therapy studies 
has advanced to clinical trials: NCT00450814, NCT00788307, NCT01503177, 
NCT01846091, NCT02068794, NCT02192775, NCT02364713, NCT03017820, 
NCT03647163. These clinical trials use genetically engineered viruses for tumor-
specific NIS transfection of various tumor entities such as multiple myeloma, ovarian 
or hepatocellular carcinoma. Although these studies are highly promising in translating 
the NIS-mediated radioiodine therapy concept to non-thyroidal tumors, the efficacy of 
this approach depends on the delivery system. In the field of non-viral vectors, 
mesenchymal stem cells (MSCs) are being intensively investigated as potential gene 
delivery vehicles due to their high lineage plasticity, selective tumor homing capacity 
and minimal ethical concerns with regards to isolation and their use. Thus, MSCs show 
great potential in improving safe and tumor-specific systemic NIS transgene delivery 
in non-thyroidal tumors.   
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1.3 Mesenchymal stem cells (MSCs) 
 
1.3.1 MSCs and tumor homing 
 
Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells, that have 
self-renewing potential and possess the ability to differentiate into various cell types 
including stromal cells, adipocytes, chondrocytes and osteocytes [42]. MSCs are 
characterized by different surface marker proteins such as CD90, CD73 and CD105, 
but must lack HLA-DR, CD34, CD45, CD19, CD11b, CD14 and CD79 [43, 44]. They 
are easy to isolate from bone marrow, adipose tissue and others [42]. Their ability to 
not only home to inflammatory sites or damaged tissues, but also to tumors, has made 
them an interesting and widely investigated tool to deliver anti-cancer agents or 
therapeutic genes to tumor sites (Fig. 3). The mechanisms underlying the directed 
MSC recruitment toward solid tumors is thought to be driven by processes similar to 
those seen in chronic wounds, where the release of certain inflammatory factors plays 
a major role in attracting MSCs [45, 46].  
 
 
Fig. 3: Schematic illustration of the tumor homing capacity of mesenchymal stem cells (MSCs) to 
tumors. Secretion of inflammatory chemokines and growth factors attract MSCs to the tumor 
microenvironment (based on Balkwill et al. [8]). 
  
Tumor cells and cells of the tumor environment release diverse factors linked to MSC 
tumor homing. In addition to growth factors such as PDGF, EGF, FGF2 and VEGF, 
cytokines and chemokines, including interleukin-6 (IL-6) and the chemokine (C-X-C 
motif) ligand 12/stromal cell-derived factor 1 (CXCL12/SDF-1), CXCL8 and the 
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pleotropic growth factor TGFB1/3, play critical roles in the MSC recruitment process 
[5, 47]. 
 
1.3.2 Genetically engineered MSCs 
 
MSCs are reasonably easy to culture and handle for genetic modifications ex vivo. 
Genetically engineered MSCs have been used to specifically target tumors and to 
deliver diverse therapeutic agents. One advantage of using MSCs as gene delivery 
vehicles is the ability to use them autologously in patients. As these cells are also hypo-
immunogenic they also allow an allogeneic application [48]. Early studies investigated 
MSCs transfected with interferon β (IFN-β) that were intravenously injected in mice 
harboring melanoma xenografts which led to decreased tumor growth and prolonged 
survival [49]. Subsequently, the ability of MSCs to act as gene delivery vehicles was 
intensively investigated in a variety of settings. MSC-mediated delivery of IFN-γ, IL-12 
or IL-24 was shown to inhibit tumor growth, whereas local production of the tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL) by MSCs within tumors led 
to the induction of apoptosis [43]. Further, HSV-TK transfected MSCs were shown to 
actively home to breast, liver and pancreas tumors, and, in combination with 
ganciclovir, resulted in reduced tumor growth [50-52]. In a phase I study, our 
collaboration partner Prof. Dr. Peter Nelson investigated genetically modified MSCs in 
combination with ganciclovir [53]. These MSCs express HSV-TK and were used in 
combination with ganciclovir for treatment of patients with advanced gastrointestinal 
adenocarcinoma demonstrating acceptable safety and tolerability in patients. MSCs 
have also been used to deliver oncolytic viruses to tumors. MSCs engineered by 
conditionally replicative adenovirus (CRAd) were applied to human glioma, lung 
metastasis as well as melanoma and breast carcinoma animal models, which resulted 
in prolonged survival and reduction of metastases [43]. Inhibition of liver carcinoma 
growth and ovarian cancer was achieved by MSCs infected with the oncolytic measles 
virus (MV) [43]. Further, approaches to induce tumor cell apoptosis have made use of 
are engineered MSCs carrying drug-loaded nanoparticles, which are able to directly 
and slowly release doxorubicin or paclitaxel in tumors [54, 55].  
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1.3.3 MSC-mediated NIS gene delivery 
 
A highly promising approach to systemically deliver the theranostic NIS transgene is 
the use of MSCs as therapy vehicles. Non-invasive tracking of MSCs transfected with 
an adenovirus construct containing NIS under control of a constitutive CMV-promoter 
was determined by radionuclide imaging experiments and therapy of mice harboring 
breast cancer [56]. Injection of NIS-MSCs made it possible to track MSC biodistribution 
as well as NIS transgene expression by radioiodine imaging prior to an application of 
a therapeutic dose of radioiodide. The therapy approach revealed a significant 
decrease of tumor growth.  
The laboratory of Christine Spitzweg in collaboration with Prof. Dr. Peter Nelson have 
investigated the potential efficacy of MSCs for the delivery of NIS into different types 
of primary tumors as well as metastases. In addition, they have examined a wide range 
of gene promoters to specifically control NIS expression within tumors and their 
micromilieu (Fig. 4) [57-60].  
 
 
Fig. 4: Stable transfection of MSCs with a plasmid containing the NIS transgene linked to a promoter to 
control NIS expression specifically in the tumor. Promoters can be designed to be activated through 
secreted factors (cytokines, chemokines or growth factors) involved in tumorigenesis, angiogenesis, 
hypoxia or other processes.  
 
The first proof-of-principle studies using NIS-transduced MSCs made use of the 
constitutively active CMV-promoter to drive NIS expression in MSCs and a 
subcutaneous mouse model of HCC [57]. Knoop et al. demonstrated high tumor-
specific radioiodide accumulation in vivo as compared to control tumors with wild-type 
MSCs. Following MSC-mediated NIS-based radioiodine therapy, a significant 
reduction in HCC tumor growth was observed [57]. To enhance tumor stroma-specific 
NIS expression, various strategies using of tissue-specific gene promoters were 
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investigated. One approach made use of the regulated on activation, normal T-cell 
expressed and secreted (RANTES)/CCL5 gene promoter to control NIS expression 
(RANTES-NIS-MSCs). Studies using subcutaneous HCC xenografts revealed an 
improved radioiodide uptake in tumors in comparison to studies using the CMV-
promoter and resulted in an enhanced therapeutic response in animals and prolonged 
survival [58]. Further, RANTES-NIS-MSCs were applied in a colon cancer liver 
metastasis model. Even in this aggressive tumor mouse model a strong therapeutic 
effect was induced after 131I application [59].  
In another approach, a synthetic gene promoter that responds to tumor hypoxia was 
examined in a subcutaneous as well as an orthotopic liver cancer mouse model. MSCs 
were transfected with a construct containing the NIS transgene linked to a hypoxia 
responsive promoter (HIF-NIS-MSCs) [60]. A significant decrease in tumor growth and 
prolonged survival was observed using the orthotopic mouse model. Although a 
stronger activation of the promoter was expected in subcutaneous tumors, as those 
tumors are more hypoxic than orthotopic ones, it seemed that in this setting MSC 
migration was the rate-limiting factor. The difference in the migratory behavior of MSCs 
to subcutaneous and intrahepatic HCC was also described by Garcia et al. [61]. This 
is thought to be based on activation of the surrounding liver cells by the cancer cells to 
secrete cytokines, chemokines and growth factors implicated in the mechanisms of 
MSC recruitment [60].   
 
1.3.4 Approaches to improve MSC-mediated NIS gene therapy   
 
The aforementioned studies point out the importance of the animal model used to 
evaluate the efficacy of MSC-based gene delivery. The earliest mouse models were 
developed by subcutaneous implantation of tumor cells in immune incompetent mice. 
Subcutaneous xenograft mouse models are easy to establish and a useful first step for 
evaluation of new therapy strategies. However, these models often fail to predict 
human response as they poorly reflect cancer heterogeneity, immune response of the 
host or existing or developed drug resistance [62]. While subcutaneous mouse models 
are important models for proof-of-principle studies, the next step towards clinical 
application are orthotopic or genetically engineered mouse models, which 
endogenously develop tumors and most reliably represent cancer development and 
features in human cancers. The next step of preclinical development of the MSC-
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mediated NIS gene therapy concept is therefore the investigation of MSCs-mediated 
NIS gene delivery in advanced and more complex mouse models.   
A further strategy, to not only improve NIS transgene delivery by MSCs but also 
enhance flexibility regarding tumor inter- and intraindividual heterogeneity, is the 
development and evaluation of novel promoters with higher specificity and efficacy to 
control NIS expression within the tumor microenvironment. Taking advantage of tumor 
characteristics, factors that are overexpressed within the tumor microenvironment can 
be used to drive NIS expression, leading to activation only upon arrival of MSCs in the 
tumor stroma.  
A promising approach offers the combination of NIS transgene therapy with existing 
therapies such as chemotherapy or radiotherapy, which is an important angle to 
enhance therapeutic outcome with regards to tumor reduction and improvement of 
survival. A limited number of studies have assessed the potential effect of radiotherapy 
and tumor homing capacity of adoptively applied MSCs [63-65]. These studies open 
an exciting aspect to improve MSC-mediated NIS radionuclide therapy. The current 
thesis investigates the potential of different strategies to enhance the potential of MSC-
mediated NIS transgene therapy.  
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2. Aims of this thesis 
 
Mesenchymal stem cells were evaluated for their tumor-homing ability to specifically 
deliver the NIS transgene deep into the tumor environment taking advantage of the 
dual role of NIS as reporter and therapy gene in multiple tumor mouse models. As a 
next step towards clinical development, the major focus of this thesis was the general 
improvement of the MSC-based NIS gene therapy.  
 
Previous studies have demonstrated successful therapeutic approaches using MSCs 
as NIS gene transfer vehicles. However, clinical transferability of studies in xenograft 
mouse models without an intact immune system is limited. Therefore, as a first aim of 
this thesis, the efficacy of systemically applied MSCs was studied in a more clinically 
relevant and suitable mouse model of advanced endogenous pancreatic ductal 
adenocarcinoma (PDAC) described as Ptf1a+/Cre;Kras+/LSL-G12D;Trp53loxP/loxP 
(Kras;p53). The Kras;p53 mouse model endogenously develops PDAC, which strongly 
reflects the human disease. Murine MSCs stably transfected with NIS under the control 
of the unspecific cytomegalovirus (CMV) promoter (NIS-MSCs) demonstrated high 
cellular NIS-specific radioiodide uptake. Systemic injection of NIS-MSCs in mice 
harboring PDAC allowed noninvasive monitoring of NIS expression by 123I-scintigraphy 
and 124I-PET imaging, as well as examination of the therapeutic potential of the NIS-
MSC-based NIS gene therapy using 131I in the Kras;p53 PDAC mouse model.  
 
Considering the high intra- and intertumoral heterogeneity the group of Prof. Dr. 
Christine Spitzweg in collaboration with the laboratory of Prof. Dr. Peter Nelson has 
been searching for new ways to express NIS more selectively within the tumor and its 
environment. The use of specifically designed promoters allows control of NIS 
expression specifically within the tumor tissue and to meet the needs of individual 
tumor types. As the pleiotropic factor TGFB is a central player in carcinogenesis and 
upregulated in a variety of tumors, a synthetic TGFB1-inducible SMAD-responsive 
promoter was designed and human MSCs were stably transfected with NIS under the 
control of this promoter (SMAD-NIS-MSCs) to potentially improve tumor specificity of 
MSC-dependent NIS gene delivery. SMAD-NIS-MSCs were characterized in vitro by 
radioiodine uptake activity assay using different doses of TGFB1 to stimulate NIS 
expression in MSCs. The potential improvement of diagnostic and therapeutic 
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application of SMAD-NIS-MSCs in a subcutaneous HuH7 xenograft mouse model was 
investigated.  
 
The next step towards optimization of the efficacy of MSC-based NIS gene therapy 
was the investigation of the effects of external beam radiation therapy (EBRT) on the 
tumor-homing capacity of MSCs to radiation pretreated tumors. Currently, there is 
growing evidence that radiation enhances MSCs recruitment to tumor sites by 
increasing the secretion of inflammatory cytokines and growth factors. As part of this 
thesis we investigated the effects of radiation treatment on the biology of the human 
hepatocellular carcinoma cell line HuH7, as well as of the human breast 
adenocarcinoma cell line MDA-MB-231, by analyzing the in vitro secretion profiles for 
different inflammatory factors involved in MSC migration. Further, the effect of 
supernatants of irradiated and non-irradiated tumor cells on MSC migration was 
examined using a 3D live cell imaging migration assay. To investigate the potential of 
radiation pretreatment on MSC tumor homing in vivo, mice harboring HuH7 xenograft 
tumors were pretreated with low doses of radiation (0, 2 or 5 Gy) followed by 
intravenous application via the tail vein of human MSCs expressing NIS under the 
control of the CMV-promoter (CMV-NIS-MSCs) followed by analysis of the tumoral 
radioiodide uptake by 123I-scintigraphy.  
 
Based on data from the studies outlined above demonstrating EBRT as potent 
stimulator of MSC homing as well as TGFB as central mediator of the inflammatory 
response underlying this effect, in the final step radiation tumor pretreatment was 
combined with the novel tumor stroma-specific SMAD-NIS-MSC therapy approach to 
evaluate the therapeutic efficacy of increased MSC recruitment and enhanced 
promoter activity of SMAD-NIS-MSCs in irradiated HuH7 tumors. In vitro, effects of 
stimulation with non-irradiated and irradiated HuH7 cell supernatants on the 
radioiodide uptake activity of SMAD-NIS-MSCs were determined. Nonirradiated as 
well as irradiated (using low-dose radiation of 5 Gy) tumors were 
immunohistochemically stained for their TGFB1 expression levels. The effect of 
radiation pretreatment on the migratory capacity and the promoter activation through 
TGFB1 in SMAD-NIS-MSCs was then evaluated in vivo using 123I-scintigraphy. 
Further, tumors were pretreated using 5 Gy followed by SMAD-NIS-MSC and 
radioiodine application to evaluate the therapeutic efficacy of this novel approach.   
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3.1 Abstract 
 
The sodium iodide symporter (SLC5A5/NIS) as theranostic gene would allow for non-
invasive imaging of functional NIS expression and therapeutic radioiodine application. 
Genetically engineered mesenchymal stem cells (MSCs), based on their tumor-homing 
abilities, show great promise as tumor-selective NIS gene delivery vehicles for non-
thyroidal tumors. Towards this clinical application, tumor specificity and efficacy of 
MSCs were investigated in an advanced genetically engineered mouse model of 
pancreatic ductal adenocarcinoma (PDAC). Syngeneic murine MSCs were stably 
transfected with a NIS expressing plasmid driven by the CMV-promoter (NIS-MSC). In 
vivo 123I-scintigraphy and 124I-PET revealed significant perchlorate-sensitive NIS-
mediated radioiodide accumulation in PDAC after systemic injection of NIS-MSCs. 
Active MSC recruitment into the tumor stroma was confirmed using NIS 
immunohistochemistry (IHC). A therapeutic strategy, consisting of three cycles of 
systemic MSC-mediated NIS delivery, followed by 131I application, resulted in a 
significant delay and reduction in tumor growth as compared to controls. Further, IHC 
analysis of α-SMA and Ki67 revealed differences in the amount and behavior of 
activated fibroblasts in tumors of mice injected with NIS-MSCs as compared to saline 
treated mice. Taken together, MSCs as NIS gene delivery vehicles in this advanced 
endogenous PDAC mouse model demonstrated high stromal targeting of NIS by 
selective recruitment of NIS-MSCs after systemic application resulting in an impressive 
131I therapeutic effect.   
Implications: These data expand the prospect of mesenchymal stem cell-mediated 
radioiodine imaging-guided therapy of pancreatic cancer using the sodium iodide 
symporter as a theranostic gene in a clinical setting. 
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3.2 Introduction 
 
The sodium iodide symporter (NIS) is an intrinsic transmembrane glycoprotein that is 
responsible for the active transport of iodide into the thyroid gland [20]. As NIS is also 
expressed in follicular cell-derived differentiated thyroid cancer cells, its expression 
provides the molecular basis for diagnostic and therapeutic application of radioiodine 
in thyroid cancer patients [20, 22]. The extensive clinical experience of using NIS as 
theranostic gene in the management of thyroid cancer patients has provided the basis 
for the development of  NIS gene-based therapy approaches in nonthyroidal tumors 
[21, 23]. The NIS transgene has been successfully transferred selectively into 
extrathyroidal tumor cells or cells of the tumor environment using various gene delivery 
systems where diagnostic use of NIS has allowed the direct monitoring and detailed 
characterization of vector biodistribution, localization and duration of transgene 
expression within tumors using 123I-scintigraphy and 124I-PET imaging [21, 28, 30, 33, 
34, 36-38, 41, 56-60, 66, 67]. The dosimetric calculations derived from the imaging 
studies allowed the application of an optimized therapeutic dose of radioiodine (131I). 
Different approaches for systemic NIS gene delivery (i.e. polyplexes, mesenchymal 
stem cells, viral vectors) are currently under evaluation in several experimental settings 
and in tumor mouse models [28, 30, 33, 34, 36-38, 41, 57-60, 66]. One promising 
approach has been the use of bone-marrow derived mesenchymal stem cells (MSCs) 
as tumor therapy vehicles based on their excellent intrinsic tumor-homing capacity [45, 
46, 52]. Their active recruitment into growing tumor stroma is mediated by mechanisms 
that are thought to be similar to those that occur in the context of wound healing [45, 
46]. Once MSCs enter the tumor environment, they differentiate into various tumor 
stroma-associated cell types [68]. These include cells associated with the tumor 
vasculature and stromal fibroblast-like cells. A series of studies have demonstrated the 
potential of using adoptively applied MSCs to deliver therapeutic genes into primary 
tumors as well as to tumor metastases [51, 52, 57-60, 65, 69]. MSC-mediated NIS 
gene delivery in xenograft tumor mouse models has shown successful selective NIS-
expression in tumors and metastases as well as a robust therapeutic response after 
131I application [57-60]. Although these results are very promising, the studies with 
implanted xenograft models often suffer from limited correlation to the human situation 
and are not ideal for clinical translation due to the immune deficient state of tumor 
carrying animals and a less than optimal tumor environment [70]. By contrast, 
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genetically engineered mouse models (GEMM) with endogenous tumor development 
represent a better model system for the evaluation of diagnostic and therapeutic tumor 
studies due to their heterogeneity on a genetic and morphological level, and their more 
complex tumor environment that better reflect that seen in cancer patients [70, 71]. 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer 
deaths in developed countries, and while surgical intervention may be effective in very 
limited cases, no effective long-term therapeutic strategies are currently available [71, 
72]. PDAC development and progression is known to involve genetic and 
morphological changes such as the activation of the KRAS oncogene and inactivation 
of TP53, a tumor suppressor also known as “guardian of the genome”. When these 
genetic changes occur in concert with the activation and malfunction of diverse growth 
factor receptors and others, the process eventually manifests as PDAC [73-76].   
Several GEMMs of PDAC have been shown to accurately recapitulate key aspects of 
the human disease, including the Ptf1a+/Cre;Kras+/LSL-G12D;Trp53loxP/loxP (Kras;p53) 
model used in the present study [73, 75, 77-79]. These mice develop extremely 
aggressive PDAC, which leads to quick fatality. The tumors are characterized by strong 
desmoplasia as well as a dynamic communication between tumor cells and its 
environment and a complex microarchitecture [75, 80]. Further, PDAC has an 
extensive tumor stroma consisting of fibroblasts, inflammatory cells and vasculature 
girded by high amounts of extracellular matrix. These tumors are also able to respond 
to treatments by remodeling and rearranging the tumor stroma [80].  
We investigated the efficacy of adoptively applied murine MSCs as gene delivery 
vehicles for tumor-selective NIS gene transfer in the Kras;p53 PDAC mouse model, a 
model that provides an important step towards studying this therapy approach in a 
clinically more relevant preclinical setting. NIS was used for noninvasive 123I-
scintigraphy and 124I-PET imaging to determine MSC localization as well as level and 
duration of transgene expression. The efficacy of a NIS gene 131I therapy approach 
was further evaluated in this advanced endogenous PDAC mouse model. 
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3.3 Materials and methods 
 
Mesenchymal stem cells 
The MSC cell line used in this study was isolated from the bone marrow of a female 
p53-/- mouse with Balb/c background (in the following referred to as wild type MSCs) 
as described previously [81]. MSCs were cultured in RPMI (Sigma-Aldrich, St. Louis, 
Missouri, USA) supplemented with 10% FBS and 100 U/ml penicillin/100 µg/ml 
streptomycin. Cells were maintained at 37°C and 5% CO2 in an incubator.  
Wild type MSCs (WT-MSC) were stably transfected with the  
expression vector CMV-NIS-pcDNA3, wherein the full length NIS cDNA is coupled to 
the cytomegalovirus (CMV) promoter. The transfection and isolation of clones as well 
as the screening for iodide uptake levels was performed as described previously [57]. 
The resulting stably transfected cell line for the following experiments was referred to 
as NIS-MSCs.  
 
125I uptake assay 
Radioiodide uptake of MSCs was determined at steady-state conditions as described 
previously [66].  
 
Quantitative real-time PCR (qRT-PCR) 
Total RNA from MSCs was extracted using the RNeasy Mini Kit with QIAshredder 
(Qiagen, Hilden, Germany). Reverse transcription and quantitative real-time PCR were 
conducted using a Mastercycler ep gradientS PCR cycler as described previously 
(Eppendorf, Hamburg, Germany) [58]. Relative expression levels were calculated from 
ΔΔCt values normalized to internal β-actin and results are expressed as fold change 
relative to controls.   
Animals 
Establishment of the Kras;p53 (Ptf1a+/Cre;Kras+/LSL-G12D;Trp53lox/loxP) strain has been 
described previously and was maintained on a mixed C57BL/6;129/Sv background [39, 
73, 82, 83]. Animals were maintained under specific pathogen-free conditions with 
access to mouse chow and water ad libitum. Both male and female mice at 4-8 weeks 
of age were used for experiments. Experiments were performed in accordance with 
institutional guidelines of the Klinikum rechts der Isar, Technische Universität München 
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and was approved by the regional governmental commission for animals (Regierung 
von Oberbayern, Munich, Germany).  
 
MSC application and 123I-scintigraphy  
Experiments started when mice were about 6-8 weeks of age and tumors were 
developed. To suppress thyroidal iodide uptake for the imaging study, mice were given 
5 mg/ml L-T4 (Sigma-Aldrich) in their drinking water. The first experimental group 
received NIS-MSCs (n=5) or WT-MSCs (n=2) three times on every second day via the 
tail vein at a concentration of 5 × 105 cells/500 µl PBS. As an additional control, 30 min 
before radioiodide administration, a subset of mice (n=2) was pretreated with 2 mg of 
the competitive NIS inhibitor sodium perchlorate (Sigma-Aldrich). 72 h after the last 
MSC application, mice received 18.5 MBq (0.5 mCi) 123I (GE Healthcare, 
Braunschweig, Germany) i.p. and radioiodide accumulation was monitored using a 
gamma camera provided with a low-energy high resolution collimator (e.cam, 
Siemens, Munich, Germany).   
The second group received only one MSC application via the tail vein of 5 × 105 
cells/500 µl PBS NIS-MSCs (n=5) or WT-MSCs (n=2) followed 48 h later by 18.5 MBq 
(0.5 mCi) 123I i.p. application and monitoring of radioiodide biodistribution as described 
above. Also, a subset of mice (n=2) were treated with perchlorate as well 30 min before 
radioiodide application.  
Analysis and Quantification of regions of interest were done using HERMES GOLD 
(Hermes Medical Solustions, Stockholm, Sweden). Results are expressed as a fraction 
of the total amount of applied radionuclide per gram tumor tissue (after post mortem 
weighing) (% ID/g). Radionuclide retention time was examined by serial scanning 
within the tumors. Dosimetric calculations for 131I were done according to the concept 
of medical internal radiation dose using the dosis factor of RADARgroup 
(www.dosisinfo-radar.com).   
 
MSC application and 124I-PET imaging   
In order to achieve a better discrimination between uptake in the tumor and the 
adjacent stomach, a 124I-PET imaging was performed. NIS-MSCs (n=5) or WT-MSCs 
(n=2) were applied three times for every second day as described above and mice 
received 10 MBq 124I (Perkin Elmer, Waltham, MA, USA) i.p. 72 h later. 30 min before 
radioiodide administration, a mouse (n=1) was pretreated with 2 mg of the competitive 
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NIS inhibitor sodium perchlorate. Using a micro PET system (Inveon, Siemens 
Preclinical Solutions, Erlangen, Germany) radioiodide biodistribution was monitored by 
static acquisition 3 h post injection.  
 
Radionuclide therapy study 
For inclusion of mice harboring PDAC, a 7T dedicated animal MR scanner was used 
for monitoring. Therapy started as soon as they fulfilled the inclusion criteria (tumor 
volume of 100-500 mm3). To monitor tumor growth, the 7T-MR imaging was done on a 
weekly basis. Following a L-T4 pretreatment as described above, three groups of mice 
were established receiving only one systemic NIS-MSCs application followed 48 h later 
by a therapeutic dose of 55.5 MBq 131I i.p. (NIS-MSCs + 131I, n=10) or, as control, 
received NaCl (saline) instead of radioiodide, (NIS-MSCs + NaCl, n=9). The therapy 
cycle consisting of systemic MSC-mediated NIS gene transfer followed by radioiodide 
was repeated for a total of three times on days 0/2, 4/6 and 7/9. The body conditions 
of the mice were closely monitored for the whole time of treatment. Mice were 
sacrificed after reaching one or more endpoint criteria (tumor volume >1000 mm3, body 
weight loss >15 %, abnormalities in physical or behavioral criteria).  
 
Immunohistochemical staining  
Immunohistochemical NIS staining of paraffin-embedded tissue sections derived from 
PDAC or non-target organs (liver, lung and spleen) after systemic NIS-MSC or WT-
MSC administration was performed as described previously [84]. Quantification of NIS 
immunohistochemical staining was performed by a highly experienced pathologist. 
Areas (1 mm2) of high NIS protein expression were defined as hot spots and the 
number of NIS-expressing MSCs within a hot spot was quantified. 
Immunohistochemistry for all other markers was performed using a Bond RXm system 
(Leica, Wetzlar, Germany, all reagents from Leica) with primary antibodies against 
Ki67 (ab16667, abcam, Cambridge UK) and α-SMA (ab124964, abcam, Cambridge 
UK). Briefly, slides were deparaffinized using deparaffinization solution, pretreated with 
Epitope retrieval solution 1 (corresponding to citrate buffer pH6) for 20 minutes. For 
single stainings, antibody binding was detected with a polymer refine detection kit 
without post primary reagent and visualized with DAB as a dark brown precipitate. For 
double stainings, after DAB visualization as described above, a second primary 
antibody was applied, and detected and visualized with a polymer refine red kit without 
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post primary reagent. Counterstaining was, in all protocols, done with hematoxyline. 
  
Stromal contents were determined by MOVAT pentachrome staining as described 
previously [80]. 
Statistical methods 
Results are expressed as mean ± SEM, mean-fold change ± SEM or, for survival plots, 
percent. Statistical significance was tested by two-tailed Student´s t-test or, for tumor 
volumes, using one-way ANOVA followed by Tukey’s Honestly Significant Difference 
test. For Kaplan-Meier plots statistical significance was analyzed by log-rank test. For 
all tests, p-values <0.05 were considered statistically significant (*p<0.05; **p<0.01; 
***p<0.001; n/s not significant). 
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3.4 Results 
 
Characterization of MSCs stably expressing NIS 
After stable transfection of bone marrow derived murine MSCs with a NIS expressing 
plasmid (CMV-NIS-pcDNA3) (NIS-MSC), NIS-MSCs showed a 38-fold increase in NIS-
mediated iodide uptake activity as compared to non-transfected wild type MSCs (WT-
MSCs) (Fig. 1A). Addition of the NIS-specific inhibitor perchlorate significantly 
decreased levels of iodide uptake in NIS-MSCs to background levels. No perchlorate-
sensitive iodide uptake above background levels could be observed in WT-MSCs.  
 
 
 
Fig. 1: Establishment of murine mesenchymal stem cells (MSCs) stably expressing the sodium iodide 
symporter (NIS). Iodide uptake studies revealed 30-fold higher NIS-specific and perchlorate-sensitive 
125I uptake in NIS-MSCs as compared to wild type MSCs, where no perchlorate-sensitive radioiodide 
uptake above background levels was observed (A). A time course experiment of NIS-MSCs and WT-
MSCs showed that NIS-MSCs reached half-maximal levels of radioiodide uptake within 15-25 min, 
obtaining saturation at approximately 50 min (B). Confirmation of NIS transgene expression was done 
using qRT-PCR revealing 6500-fold higher NIS mRNA expression of NIS-MSCs as relatively compared 
to WT-MSCs (C). Data are represented as mean values ± SEM (n=3; two-tailed Student’s t-test: *P<0.05; 
**P<0.01, ***P<0.001). 
 
A time course of iodide uptake in NIS-MSCs (and WT-MSCs controls) identified half-
maximal levels of radioiodide accumulation within 15-25 min, and a saturation of 
uptake at approximately 50 min in the NIS-MSCs whereas no NIS-specific iodide 
uptake was observed when cells were treated with perchlorate (Fig. 1B).  
The expression levels of steady state NIS mRNA in the NIS-MSC and WT-MSCs were 
validated using qRT-PCR. NIS was significantly higher expressed at relative mRNA 
levels (approximately 6500-fold) in NIS-MSCs as compared to WT-MSCs (Fig. 1C).  
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In vivo imaging studies reveal high NIS-mediated radioiodide accumulation in 
PDAC 
To compare the general efficacy of MSC-mediated NIS gene delivery and radioiodide 
uptake activity using 123I-scintigraphy in mice harboring endogenous PDAC with the 
results of earlier studies in xenograft mouse models, a group of mice received three 
applications at two-day intervals of NIS-MSCs (5 x 105 cells, intravenously (i.v.) via the 
tail vein) or WT-MSCs, followed by a single radioiodide application (18.5 MBq 123I, 
intraperitoneally (i.p.))  72 h later – the application regimen that we had applied in our 
previous studies. While no radioiodide accumulation above background levels was 
detected in tumors of mice receiving WT-MSCs (Fig. 2C), significant iodide 
accumulation was observed in tumors of mice which had received NIS-MSCs (Fig. 2A). 
Physiologic iodide accumulation was observed in the thyroid and salivary glands (SG), 
stomach and bladder (Fig. 2A, C). As determined by serial scanning, a maximum of 
approximately 16.2 ± 2.9 % injected 123I dose per gram (ID/g) tumor was accumulated 
after three cycles of NIS-MSCs application which showed a biological half-life of 7 h, 
and a calculated tumor absorbed dose of 136.9 mGy/MBq 131I (Fig. 2I). To confirm that 
tumoral iodide uptake was NIS-mediated, a subset of mice treated with NIS-MSCs 
received perchlorate 30 min prior to 123I administration. Perchlorate treatment 
completely blocked tumoral iodide accumulation as well as iodide uptake in stomach 
and thyroid gland (Fig. 2B). To assess an optimized, less time intense treatment 
schedule more applicable in the rapidly growing tumor model, an additional 123I-
scintigraphy experiment was performed with only one MSC application (Fig. 2G, H). 
PDAC harboring mice received only one NIS- or WT-MSC application followed by an 
injection of 18.5 MBq 123I 48 h later. Radioiodide distribution revealed significant 
radiodide accumulation in the tumors (Fig. 2G), while no iodide accumulation was 
detected in tumors of mice receiving perchlorate 30 min prior to 123I administration (Fig. 
2H). As determined by serial scanning, a maximum of 16.3 ± 2.3 % ID/g 123I was shown 
to accumulate after a single NIS-MSC application, with a biological half-life of 4 h, and 
a calculated tumor absorbed dose of 100.7 mGy/MBq 131I (Fig. 2I). While the maximum 
radioiodide uptake obtained in this experiment was approximately the same as that 
seen in the first experimental setting, radioiodide efflux was slightly more rapid and 
biological half-life was shorter, however the overall tumor absorbed dose of 131I was 
only mildly reduced.  
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Fig. 2: 123I-scintigraphy and 124I-PET imaging revealed high pancreatic tumoral radioiodide uptake. One 
(A) or three (G) systemic injections of NIS-MSCs in mice harboring PDAC resulted in a maximum of 
approximately 16.2 % to 16.3 % of injected dose per gram (ID/g) tumor (n=5) (I). Tumor radioiodide 
uptake was NIS-specific as shown by perchlorate-sensitivity (n=2) (B, H). Treatment with WT-MSCs 
showed no NIS-specific tumoral radioiodide uptake (n=2) (C). Further, application of three i.v. injections 
of NIS-MSCs on every second day confirmed high perchlorate-sensitive NIS-specific tumoral iodide 
uptake using 124I-PET (n=1-5) (D, E). Also, no tumoral radioiodide accumulation was observed after 
applications of WT-MSCs (n=2) (F). One representative image is shown each. Data are represented as 
mean values ± SEM. 
 
124I-PET imaging allowed a detailed 3D-analysis of tumoral iodide uptake. 3 h after 
injection of 10 MBq 124I in a subset of mice that had received three NIS-MSCs 
applications every second day (Fig. 2D-F). PET-imaging confirmed a significant tumor-
selective iodide accumulation, which was blocked upon perchlorate treatment (Fig. 2D, 
E). No iodide uptake in tumors above background levels was observed when mice 
were injected with WT-MSCs (Fig. 2F).  
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NIS protein expression in PDAC 
In order to correlate the in vivo imaging data with NIS protein expression within the 
tumors and control organs (liver, spleen, lung), tissues were dissected and 
immunohistochemically stained. NIS-specific immunoreactivity was detected in tumors 
of mice that received NIS-MSCs applications demonstrating efficient MSC-mediated 
NIS transgene expression in PDAC after systemic application (Fig. 3A, F). MSCs 
genetically engineered to express NIS were localized within the tumor stroma based 
on detection of NIS-specific immunostaining (Fig. 3A, F, arrows). NIS-specific 
immunoreactivity was detected at the membrane and in the cytoplasm of MSCs in 
tumors of mice that received NIS-MSCs applications demonstrating efficient MSC-
mediated NIS transgene expression in PDAC after systemic application (Fig. 3A, F). 
The cytoplasmic staining results from NIS protein that is not properly targeted to the 
membrane after NIS transduction of MSCs. While there was no clear visual difference 
detectable in NIS expression of tumors in mice receiving just a single (Fig. 3F) or three 
NIS-MSCs applications (Fig. 3A), a pathologist-based quantification of the amount of 
NIS-positive MSCs within PDAC showed following results: the analysis of hot spots (1 
mm2) revealed an average of 4.3 hot spots with a total of 18.3 NIS-positive MSCs within 
tumors of mice receiving a total of three MSC applications and an average of 10.3 hot 
spots with a total of 32 NIS-positive MSCs within the group receiving only MSCs once. 
Lung, liver and spleen showed no detectable NIS protein expression (Fig. 3B-I). Mice, 
which received three applications with WT-MSCs showed no NIS protein expression 
in tumors (Fig. 3E).  
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Fig. 3: High NIS protein expression in PDAC tumors. NIS-specific immunoreactivity (red) was detected 
in PDAC after systemic application of NIS-MSCs (black arrows) (A, F). No NIS protein expression was 
seen in nontarget organs (B-D, G-I) or tumors of mice, which received WT- MSCs (E). One 
representative image is shown each using 20x magnification or also 40x magnification for tumors 
showing NIS specific immunoreactivity. 
 
Therapeutic application of radioiodine 131I 
A relatively short therapy cycle after imaging-guided standardized detection of 
advanced local tumor growth was chosen given the aggressive nature of tumor growth 
in this model. Based on the NIS imaging results after only one NIS-MSC application 
(Fig. 2G-I), the therapy study was performed with three cycles of one NIS-MSC 
application, followed by 131I injection 48 h later (Fig. 4). Mice were then monitored on 
a 7T dedicated animal MR scanner as soon as they fulfilled the inclusion criteria. 
Treatment with NIS-MSCs started on the day of the inclusion scan.  
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Fig. 4: 131I therapy study led to a delay in tumor growth. For in vivo radionuclide therapy studies, therapy 
mice received a single NIS-MSC application followed by 55.5 MBq 131I 48 h later and this cycle was 
repeated to a total of three (n=10). Therapy mice harboring PDAC resulted in a significant delay in tumor 
burden (A, C, D) as compared to controls receiving NIS-MSCs and NaCl instead (n=9) (A, E, F) or NaCl 
only (A). However, no significantly improved survival was observed (B). 
 
The MR imaging was done on a weekly basis to closely monitor PDAC growth kinetics 
(Fig. 4A). Tumor analysis of the different groups revealed a significant delay and 
reduction of tumor burden of the animals in the therapy group (NIS-MSCs + 131I) (Fig. 
4A, C, D) as compared to control groups (NIS-MSCs + NaCl (Fig. 4A, E, F) and NaCl 
+ NaCl (Fig. 4A)) [39].  After an initial exponential growth in all groups, which was 
significantly decreased in therapy mice, a plateau occurred in the therapy group with 
almost complete stop of tumor growth (Fig. 4A). However, no significant difference in 
survival was detected (Fig. 4B).  
 
Histological and immunohistochemical analysis 
Morphologically, there were only slight differences between the pancreatic neoplasia 
of all groups. All tumors were moderately to poorly differentiated and showed 
predominantly ductal growth patterns. No tumor cell necrosis or apoptosis as signs of 
tumor regression were observed after treatment. Interestingly, in animals receiving 
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NIS-MSCs, stroma content (consisting of cancer-associated fibroblasts and 
extracellular matrix (glyco-) proteins) was more pronounced. 
 
 
Fig. 5: Immunohistochemical analysis. In tumors of mice receiving NIS-MSCs and saline, movat staining 
demonstrated a significant increase of collagen fibers as compared to mice receiving saline only (A-C, 
G). Also, in tumors of mice receiving NIS-MSCs + 131I a more modest increase (not reaching statistical 
significance) of collagen fibers was observed. No difference in extracellular interstitial or intracellular 
mucin was observed (A-C, G). Ki67 staining detected more proliferating cells within the tumor and 
stroma of mice receiving NIS-MSCs as compared to mice receiving saline only (D-F, H). A double stain 
for Ki67 and the activated fibroblast marker α-SMA (I-K) revealed α-SMA-positive fibroblasts within the 
neoplasia of all mice, regardless of the treatment, but differed in the arrangement within the tumor and 
stroma (black arrows) (I-K). In the control group, which received saline only, no Ki67-positive fibroblasts 
were detected (I). Single α-SMA-positive proliferating fibroblasts were visible within the tumor stroma of 
mice receiving NIS-MSCs (J, K). One representative image is shown each using 5x (Movat staining), 
10x (Ki67 staining) or 20x as well as 40x (Ki67 and α-SMA double staining) magnification. Data are 
represented as mean values ± SEM (*P<0.05; **P<0.01, ***P<0.001). 
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To further analyze the changes within the tumor microenvironment due to the presence 
of MSCs, further immunohistochemical analysis of tumors was performed. Movat 
staining revealed a significant increase of collagen fibers within tumors of mice 
receiving NIS MSCs + NaCl, as well as a more modest increase (not reaching statistical 
significance) in therapy mice (NIS-MSCs + 131I) as compared to tumors of control mice 
that received no MSCs (NaCl + NaCl) (Fig. 5A-C, G). No change in extracellular 
interstitial or intracellular mucin was seen between the different groups (Fig. 5A-C, G). 
Quantification of proliferating cells (Ki67) within the tumor and stroma cells showed a 
higher number of Ki67 positive cells within the tumor stroma of mice receiving NIS-
MSCs as compared to mice receiving saline only (NaCl + NaCl) (Fig. 5D-F, H), a double 
stain for Ki67 and the activated fibroblast marker α-SMA was performed to determine 
if fibroblasts are proliferating within the tumor stroma (Fig. 5I-K). As expected, α-SMA 
positive fibroblasts were detected within the neoplasia of all mice, regardless of the 
treatment. In animals that received saline only, the fibroblasts were loosely arranged 
between tumor cell nests and ducts, and no proliferating fibroblasts were detected (Fig. 
5I). In contrast to those findings, in tumors of mice receiving NIS-MSCs + NaCl or NIS-
MSCs + 131I an increased number of α-SMA positive fibroblasts surrounding the tumor 
cell nests and ducts were detected, often building one to two layers completely 
surrounding the neoplastic cells (Fig. 5J, K). Single fibroblasts displayed double 
positivity for α-SMA and Ki67 (Fig. 5J, K). Stainings for CD45, CD11b, F4/80, CD206 
and cleaved Caspase-3 revealed no differences in intratumoral cell numbers between 
the groups. 
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3.5 Discussion 
 
Due to the increasing incidence and lack of effective therapeutic options, pancreatic 
cancer may become the second leading cause of cancer deaths by 2030, illustrating 
the urgent need for new therapeutic strategies [85]. Various combinations of 
chemotherapies have shown some degree of therapeutic efficacy and slightly 
increased overall survival, but are accompanied by high toxicity [71, 86, 87]. Our 
increasing understanding of the central molecular targets and the pivotal role of the 
microenvironment and its regulation in PDAC, has suggested new directions for the 
development of novel therapeutic strategies. GEMMs provide a far better platform for 
the evaluation of these novel therapy strategies, and for the prediction of a therapy 
response, with a better perspective for subsequent translation to the clinic. We 
evaluated the effects of a MSC-mediated NIS-based radionuclide therapy approach in 
a GEMM showing a complex and prominent desmoplastic component. Our previous 
studies of NIS-based gene transfer using MSCs as delivery vehicles have shown 
excellent tumor homing and expression of the NIS transgene in MSCs, as well as 
significant therapeutic effects after 131I treatment in subcutaneous and orthotopic 
xenograft models of human hepatocellular carcinoma and colon metastases. In the 
present study, we have built on these studies to further evaluate the MSC-mediated 
NIS gene therapy approach in a more challenging and clinically highly relevant PDAC 
mouse model [57-60]. An important advantage of the NIS therapy gene is its additional 
role as a reporter gene, allowing noninvasive monitoring by 123I-scintigraphy and/or 
124I-PET-imaging. 123I-scintigraphy of previous studies revealed a radioiodide uptake of 
7-9 % ID/g tumor using the same CMV-NIS construct introduced into human MSCs, 
which were adoptively applied in nude mice harboring subcutaneous tumors from a 
human hepatocellular carcinoma cell line (HuH7) [57]. In comparison, the 123I-
scintigraphy data shown here demonstrate with both MSC application schemes an 
impressive level of tumor-selective MSC recruitment and NIS transgene expression in 
endogenous PDAC with an almost 100% increase in radioiodide uptake activity per 
gram tumor. However, the iodide efflux was slightly faster in the group with only one 
MSC application as compared to the group receiving a total of three MSC applications. 
As the tumoral iodide uptake and calculated tumor absorbed dose of 100.7 mGy/MBq 
for 131I was expected to be high enough for a therapy effect, based on past experience, 
we conducted the therapy study using the single NIS-MSC application regimen. We 
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observed a significant delay in tumor growth in the therapy group that received NIS-
MSCs followed by 131I in addition to a plateau in tumor growth between the first and 
second week as compared to control groups, which showed continued growth over the 
entire observation period [39]. Interestingly, a slight plateau in tumor growth between 
week one and two was also seen in the control group receiving NIS-MSCs and NaCl.  
The results shown here are in line with some studies demonstrating a general inhibitory 
effect of MSCs on tumor growth [88-91]. Kidd et al. detected significant tumor 
suppression by MSCs using an orthotopic pancreatic carcinoma xenograft mouse 
model [90]. Similarly, Nakamura et al. demonstrated reduced tumor growth in a rat 
glioma model induced by MSCs [90, 91]. Further, MSCs were shown to down-regulate 
the protein kinase Akt in Kaposi’s sarcoma tumor cells in vitro, resulting in tumor growth 
inhibition [89]. Another study using human stromal cells derived from adipose tissue, 
which share many characteristics of MSCs, demonstrated a dose-dependent inhibitory 
effect on proliferation of PDAC-derived Capan-1 cells in vitro as well as in vivo, where 
reduced tumor growth was seen in Capan-1 xenograft tumors [88]. Further, less 
proliferation and even an induction of tumor cell death was observed in vitro using 
conditioned medium from stromal cells derived from adipose tissue and MSCs. This 
effect was driven by inhibition of the cell cycle G1-phase [88]. Taken together, these 
studies suggest that MSCs are able to modulate and influence cancer cells in their 
proliferative and apoptotic behavior and this might explain the phenomenon seen in 
our therapy trial. Another aspect worth looking at is the tumor stroma. Previous studies 
point out the tumor-suppressive, rather than supportive, role of the tumor stroma and 
its compartments in PDAC [92, 93]. Rhim et al. suggest that specific components of 
the tumor stroma, such as myofibroblasts among others, play a tumor-suppressive role 
[93]. Furthermore, fibrosis associated with myofibroblasts and type-1 collagen seems 
to have rather a protective role for the host than a supportive role for pancreatic cancer 
[92]. In the present study we were able to demonstrate a change in the content of 
collagen fibers in tumors of mice that were injected with NIS-MSCs, as compared to 
tumors without MSCs (NaCl-NaCl group). These findings go along with the observation 
that some types of collagens are more likely to be tumor-suppressive [92]. Further, a 
major difference in the number of proliferating cells was observed in tumors containing 
NIS-MSCs as compared to tumors without. In contrast to those findings, former studies 
of our group, using subcutaneous or orthotopic liver carcinoma as well as colon cancer 
liver metastasis mouse models, demonstrated a significant decrease of proliferating 
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tumor cells of therapy tumors as compared to control groups [57, 58, 60]. Completely 
unexpected in the current study, we observed a significant increase of Ki67 in tumors 
containing NIS-MSCs (therapy and control group) as compared to tumors without 
MSCs (saline only). As it seemed that in both groups receiving NIS-MSCs proliferating 
cells were rather cells of the stromal compartment than tumor cells, we performed a 
Ki67 and α-SMA double staining to examine the content and proliferating potential of 
fibroblasts within these groups. Results demonstrated a higher content of activated 
fibroblasts within the tumor stroma of tumors containing NIS-MSCs as compared to the 
saline only control group. Further, it was observed that fibroblasts were located 
immediately around tumor cell nests and infiltrative ducts, which was not seen in the 
absence of NIS-MSCs. These findings resemble observations in human pancreatic 
tumors, where cancer-associated fibroblast (CAFs) are also densely arranged around 
the tumorous structures [94]. How these CAFs affect tumor development and growth 
is not fully understood yet. Some studies suggest that they promote tumor growth and 
that an increased number of α-SMA-positive myofibroblasts is associated with a poor 
prognosis, whereas other studies, as already discussed and which corroborate our 
findings, allot fibroblasts a rather protective role for the host [95]. Altogether the data 
presented here suggest that the systemically applied NIS-MSCs are actively recruited 
to the growing pancreatic carcinoma stroma, where they seem to influence the 
proliferation of various tumor associated cells through their secretion of growth factors 
resulting in increased Ki67 stain and altered arrangement of α-SMA-positive cells. As 
NIS-MSCs should be destroyed in the context of 131I treatment, the described 
processes would already take place before radioiodine treatment. Further 
investigations of changes in CD45, CD11b, F4/80, CD206 and cleaved Caspase-3 did 
not reveal differences between therapy and control groups and showed rather a 
heterogeneous staining within the same group. However, a focus on secondary effects 
of MSC delivery on intratumoral immune cell regulation is a key aim in future studies 
albeit beyond the scope of this current work. Although our findings demonstrated 
changes in the composition of the tumor stroma and the tumor micromilieu, the exact 
mechanisms underlying the reduced tumor growth in this mouse model under our 
experimental conditions have to be further investigated. A more intensive investigation, 
taking the tissue complexity of PDAC into consideration as well as the ability of MSCs 
themselves to modulate the tumor microenvironment, might provide the possibility to 
use MSCs not only for targeted therapy but also in combination with chemotherapy or 
  Chapter 1 
 
37 
 
immune approaches.  
 Although tumor growth was significantly reduced in the present study, no prolonged 
survival was observed in mice receiving treatment likely due to the overall highly 
aggressive course of disease in this model. Mice in the control group receiving NIS-
MSCs and NaCl had to be sacrificed as early as 9 days after treatment start, whereas 
the first mice in the therapy group had to be sacrificed at day 16. Around that time, 
therapy mice showed rapid health deterioration and had all to be sacrificed within a 
few days. Despite smaller tumors, these mice showed adverse symptoms such as 
ascites or icterus, which also occurred in the control group and were reasons for 
sacrifice.  
Recently our group had also reported the application of the NIS gene therapy approach 
in the same PDAC GEMM using EGFR-targeted polyplexes for NIS transgene delivery, 
which resulted in tumor reduction and prolongation of survival [39]. Polyplexes based 
on linear polyethylenimine (LPEI) are accompanied by endogenous cytotoxic effects. 
While these effects were not seen in former studies using subcutaneous xenograft 
mouse models, toxicity to the LPEI-based polyplexes was observed in Kras;p53 mice. 
In contrast to those findings, MSCs did not show toxic side effects in animals of former 
studies as well as of the current study using the same PDAC mouse model. For this 
mouse model, MSCs thus might be a better choice for NIS-mediated radioiodine 
therapy. Our results demonstrate the potential of genetically modified MSCs in PDAC 
to reduce tumor growth. We are aiming at further optimization of MSC-mediated NIS 
gene therapy approach to enhance therapeutic efficacy. For proof-of-principle of MSC-
mediated NIS gene delivery in this PDAC model, the unspecific CMV-promoter was 
used to control NIS expression. More specific promoters with enhanced tumor-
specificity specifically designed for the respective tumor environments are currently 
under evaluation. Recent studies using a tumor stroma-specific RANTES/CCL5 
promoter in an orthotopic liver metastases mouse model led to reduced metastases 
growth and improved survival of animals [59]. Further, as hypoxia is a common feature 
in tumors driving angiogenesis and resistance to conventional therapies, a synthetic 
hypoxia inducible factor (HIF)-responsive promoter was designed to target NIS 
expression into hypoxic tumor cells in an orthotopic HCC xenograft mouse model by 
our group, resulting in reduced tumor growth and prolonged survival [60]. Using a 
tumor-specific promoter designed for the tumor stroma of PDAC might enable 
increased NIS transgene expression and improved therapeutic efficacy of radionuclide 
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therapy. Additionally, application of the alternative radionuclide 188Re instead of 131I will 
be considered for therapy. 188Re is also transported by NIS and offers different 
advantages compared to 131I: it provides the possibility to enhance tumor absorbed 
doses due to higher energy and shorter half-life, and is associated with an increased 
crossfire effect due to a longer path length (up to 10.4 mm as compared to 131I with 2.4 
mm) [58]. A further option for improvement would be the combination with 
radiosensitizing agents, such as gemcitabine – a commonly used chemotherapeutic 
drug in pancreatic cancer, to increase radiosensitivity of tumors, which in turn might 
lead to enhanced therapeutic effectiveness of MSC-based NIS-mediated radioiodine 
therapy. 
Taken together, our results show great potential of MSC-mediated NIS gene delivery 
in PDAC. Adoptively applied NIS-MSCs were actively recruited to PDAC in a highly 
efficient manner resulting in high tumor-specific radioiodide uptake as confirmed by 
123I-scintigraphy and 124I-PET imaging. The translation of these results into a therapy 
study showed significantly delayed and reduced tumor growth. Our data also 
demonstrate the high potential of the application of NIS reporter gene imaging for 
monitoring and planning of a NIS gene therapy approach in PDAC in a clinical setting.
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4.1 Abstract 
 
Based on their excellent tumor-homing capacity, genetically engineered mesenchymal 
stem cells (MSCs) are under investigation as tumor-selective gene delivery vehicles. 
Transgenic expression of the sodium iodide symporter (NIS) in genetically engineered 
MSCs allows noninvasive tracking of MSC homing by imaging of functional NIS 
expression as well as therapeutic application of 131I. The use of tumor-stroma activated 
promoters can improve tumor-specific MSC-mediated transgene delivery. The 
essential role of transforming growth factor B1 (TGFB1) and the SMAD downstream 
target in the signaling between tumor and the surrounding stroma makes the biology 
of this pathway a potential option to better control NIS expression within the tumor 
milieu. Bone marrow-derived MSCs were stably transfected with a NIS-expressing 
plasmid driven by a synthetic SMAD-responsive promoter (SMAD-NIS-MSCs). 
Radioiodide uptake assays revealed a 4.9-fold increase in NIS-mediated perchlorate-
sensitive iodide uptake in SMAD-NIS MSCs after TGFB1 stimulation compared to 
unstimulated cells demonstrating the successful establishment of MSCs which induce 
NIS expression in response to activation of TGFB1 signaling using a SMAD-responsive 
promoter. 123I-scintigraphy revealed significant tumor-specific radioiodide 
accumulation and thus NIS expression after systemic application of SMAD-NIS-MSCs 
into mice harboring subcutaneous tumors derived from the human hepatocellular 
carcinoma (HCC) cell line HuH7, which express TGFB1. 131I therapy in SMAD-NIS-
MSCs-treated mice demonstrated a significant delay in tumor growth and prolonged 
survival. Making use of the tumoral TGFB1 signaling network in the context of MSC-
mediated NIS gene delivery is a promising approach to foster tumor stroma-selectivity 
of NIS transgene expression and tailor NIS-based gene therapy to TGFB1-rich tumor 
environments.  
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4.2 Introduction 
 
Therapeutic options for hepatocellular carcinoma (HCC) are limited and novel targets 
and therapeutic strategies are urgently needed considering the increasing incidence of 
HCC worldwide [2, 72]. Solid tumors are thought to be seen by the body as “wounds 
that never heal” driving tissue repair and remodeling with active recruitment of 
mesenchymal stem cells (MSCs). This biology has been used to generate engineered 
versions of adoptively applied MSCs as a tool to deliver therapeutic genes, such as 
the sodium iodide symporter (NIS), deep into tumor microenvironments [45, 46]. NIS 
is an intrinsic transmembrane glycoprotein with 13 putative transmembrane domains 
that mediates the active transport of iodide into the thyroid. When used in the context 
of a reporter gene, NIS can be used for noninvasive imaging of NIS transgene 
biodistribution by well-established multimodal nuclear medicine techniques, such as 
123I-scintigraphy and 124I-PET imaging. At the same time, it can be used as an effective 
therapy gene after application of radioiodine 131I [20-23]. A diverse series of studies 
have demonstrated the efficacy of NIS-mediated radioiodide accumulation in a variety 
of non-thyroidal tumors using different gene delivery vehicles for NIS transgene 
expression [28, 30, 33, 34, 36-38, 41, 56-60, 96-101]. The use of genetically 
engineered MSCs to deliver NIS into various types of tumors has been demonstrated 
in many studies [56-60]. Although these results have shown comparably high levels of 
NIS transgene expression in the tumor microenvironment followed by  a therapeutic 
effect of 131I, with a delay in tumor growth and prolonged survival of treated animals, 
the use of specific gene promoters for NIS expression that are activated by tumor 
micromileu-derived signals has been shown to enhance selectivity and effectiveness 
and limit potential off-target effects following MSC recruitment to tissues as part of 
normal tissue homeostasis [28, 30, 33, 34, 36-38, 41, 57-60, 81]. We have studied 
various gene promoters for the delivery of MSC-transgene expression in tumor stroma. 
These include a RANTES (Regulated on Activation, normal T-cell Expressed and 
presumably Secreted)/CCL5 promoter activated by proinflammatory signals in tumor 
settings and a synthetic hypoxia-inducible factor (HIF)1-responsive promoter that 
selectively activates NIS transgene expression in tumors by targeting hypoxia, a 
central feature of solid tumors [58-60]. The use of gene promoters activated by 
micromilieu-derived signals also offers the possibility of tailoring the NIS-therapy 
approach to the individual tumor micromilieu. The transforming growth factor B (TGFB) 
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signaling pathway is strongly linked to the biology of tumor cells and their 
microenvironment. The TGFB signaling pathway is involved in cell growth, apoptosis, 
invasion, angiogenesis and immune response regulation [102]. The isoforms of TGFB 
(TGFB1, -B2 and -B3) bind to heteromeric complexes of type I and II transmembrane 
Ser/Thr kinase receptors leading to transphosphorylation of the GS domain of the type 
I kinase through the type II receptor kinase resulting in phosphorylation of downstream 
target proteins such as SMADs [103-105]. Activated SMAD2 and SMAD3 form 
heterotrimeric complexes with the signal mediator SMAD4. The complex translocates 
to the nucleus to modulate transcription of target genes. Inhibitory SMADs, such as 
SMAD6 and SMAD7, interfere with the type I receptors, thereby blocking 
phosphorylation of other SMADs [106]. SMAD7 expression is also driven by TGFB 
signaling thus inducing a TGFB-induced negative feedback loop [106]. Depending on 
early or late steps of carcinogenesis, some tumors are able to shut down the tumor-
suppressive part of this signaling pathway thereby restricting it to pro-tumoral effects 
[107]. TGFB is present in the micromileu of most tumors [108]. In addition to the tumor 
cells, cancer-associated fibroblasts (CAFs) and stellate cells of the surrounding tumor 
stroma also secrete TGFB to control inflammatory response [102, 107]. CAFs and 
stellate cells can promote tumor growth and metastasis among others [107]. The TGFB 
pathway is strongly associated with HCC as it is well known to be dysregulated in these 
tumors [106]. Several studies demonstrated that in almost 50% of HCCs TGFB 
signaling is significantly upregulated [109, 110]. TGFB plays an important role in tumor 
angiogenesis and its regulation in HCC [102]. From the three different isoforms of 
TGFB (TGFB1, -B2 and -B3), TGFB1 is most commonly upregulated isoform in cancer 
cells [103]. The critical role of TGFB1 in HCC tumor biology makes the TGFB signaling 
pathway a promising tool for targeting NIS transgene expression by engineered MSCs 
in experimental HCC, with the aim to enhance tumor stroma selectivity and improve 
therapeutic effectiveness. 
In the current study, we used a TGFB1-inducible SMAD-responsive promoter to control 
NIS transgene expression in genetically engineered human MSCs. After adoptively 
applying MSCs in HCC xenografts, MSC biodistribution and biological targeting of NIS 
expression to the tumor stroma through NIS-mediated accumulation of radioiodide was 
examined by 123I-scintigraphy. Therapeutic efficacy was determined by 131I application 
after systemic MSC-mediated NIS transgene delivery. 
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4.3 Materials and methods  
 
Cell culture 
The human hepatocellular carcinoma cell line HuH7 was authenticated and purchased 
from JCRB Cell Bank (JCRB 0403, Osaka, Japan). Cells were cultured in DMEM 
(Sigma-Aldrich, St. Louis, Missouri, USA) supplemented with 10% FBS (FBS Superior, 
Biochrom/Merck Millipore, Berlin, Germany) and 100 U/ml penicillin/100 µg/ml 
streptomycin (Sigma-Aldrich). The human breast adenocarcinoma cell line MDA-MB 
231 was cultured in RPMI (Sigma-Aldrich), supplemented with 10% FBS and 100 U/ml 
penicillin/100 µg/ml streptomycin. The human bone marrow-derived, SV40 large T 
antigen immortalized MSC cell line used here was established as described previously 
[111] and cultured in RPMI (Sigma-Aldrich), supplemented with 10% FBS and 
100 U/ml penicillin/100 µg/ml streptomycin. The easily engineered and expandable 
cells were previously shown to demonstrate similar homing and activation 
characteristics as seen in primary human MSCs (Von Luttichau, et al. 2005). All cells 
were maintained in an incubator at 37°C and 5% CO2. 
 
Plasmid constructs  
The expression vector pcDNA6-2ITRNEO-SMAD-NIS was established using the 
Multiside Gateway Pro Plus Kit (Invitrogen Thermo Scientific, Waltham, 
Massachusetts, USA) following the manufacturer’s instructions. The promoterless 
Gateway destination vector (pcDNA6) contains a Sleeping Beauty transposon system 
as described previously [112]. The used SMAD-responsive promoter consists of a 5× 
multimer of the SMAD binding site AGCCAGACAGT. The vector pSBTR.TGF/SMAD2 
containing the promoter was established as described previously [112]. Full length NIS 
cDNA was removed from the pcDNA3 expression vector and was cloned into the 
vectors provided in the Multiside Gateway Pro Plus Kit. After a 2-fragment 
recombination the pcDNA6-2ITRNEO-SMAD-NIS plasmid was obtained. The resulting 
plasmid contains the NIS gene driven by a SMAD-responsive promoter, two sleeping 
beauty transposition sites and a geneticin resistance gene. The vectors 
pSB.H.CMV/TO.SMAD3 (expressing SMAD3) and pSB.H.CMV/TO.SMAD4 
(expressing SMAD4) were constructed as described previously [112]. 
 
Stable transfection of MSCs 
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Wild type MSCs (WT-MSC) were stably transfected with the pcDNA6-2ITRNEO-
SMAD-NIS expression vector in combination with the pCMV(CAT)T7-SB100X plasmid 
(provided from Z Ivics, Max Delbrück Center for Molecular Medicine, Berlin, Germany). 
The pCMV(CAT)T7-SB100X vector contains a Sleeping Beauty transposase system 
for transgene insertion into the host cell genome. 0.5 × 106 MSCs and a total amount 
of 3 µg plasmid were electroporated at 1300 V, 30 ms width and 1 pulse using the 
Neon® transfection system (Invitrogen, Karlsbad, California, USA). Selection medium 
was given 24 h after electroporation and contained 0.5 mg/ml geneticin (Invitrogen) in 
RPMI medium supplemented with 10% fetal bovine serum and 
100 U/ml penicillin/100 µg/ml streptomycin. The resulting clones were isolated and 
analyzed for NIS-mediated radioiodide uptake activity using an iodide uptake assay 
(see below). Among ~40 screened colonies, the stably transfected cell clone with the 
highest levels of iodide accumulation was termed SMAD-NIS-MSC and used for further 
experiments.  
For a more precise investigation of the SMAD-responsive promoter, SMAD-NIS-MSCs 
were further stably transfected with pSB.H.CMV/TO.SMAD3 (SMAD-
NIS-MSCs+SMAD3), pSB.H.CMV/TO.SMAD4 (SMAD-NIS-MSCs+SMAD4), 
pSB.H.CMV/TO.SMAD3 and pSB.H.CMV/TO.SMAD4 (SMAD-
NIS-MSCs+SMAD3+SMAD4) vector. For cells transfected with expression vectors for 
SMAD3 and/or SMAD4, 0.2 mg/ml Hygromycin was added to the cell culture medium 
described above. This stably transfected cell lines were maintained and tested as bulk 
cultures. 
 
Tumor cell conditioned medium  
1×106 HuH7 or MDA-MB 231 cells were seeded on 100 mm3 surface cell culture plates 
and starved for 12 h. Supernatant from the tumor cells (HuH7 conditioned medium 
(HuH7-CM) or MDA-MB 231-CM) was removed after 48 h, centrifuged and stored at -
80°C.  
 
125I uptake assay 
Inducibility of the promoter was determined by starving cells overnight (medium without 
FBS) followed by stimulation of SMAD-NIS-MSCs and variants of those (see above) 
with 0-25 ng/ml recombinant TGFB1 for 24h in normal medium as described above. 
NIS-mediated radioiodide uptake was determined at steady-state conditions as 
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described previously by Spitzweg et al. [66]. Results were normalized to cell viability. 
 
Cell viability assay 
Cell viability was measured using the commercially available MTT assay (Sigma-
Aldrich, ratio 1:100) according to the manufacturer’s recommendations. For the 
measurement of the absorbance of the formazan product at a wavelength of 620 nm, 
a Sunrise Microplate Absorbance Reader (Tecan, Männedorf, Switzerland) was used. 
 
Animals 
Female 5-week-old CD1 nu/nu mice from Charles River (Sulzfeld, Germany) were 
housed under specific pathogen-free conditions. Mice had access to mouse chow and 
water ad libitum. Experiments were approved by the regional governmental 
commission for animals (Regierung von Oberbayern). 
 
HuH7 xenograft tumors 
For HuH7 xenograft tumor establishment, 5 × 106 HuH7 cells in 100 µl PBS were 
injected subcutaneously into the right flank region as described previously [57]. Tumor 
volumes were regularly measured and estimated using the equation: length × width × 
height × 0.52. Mice were sacrificed when tumors exceeded a size of 1500 mm3. 
 
123I-scintigraphy  
To suppress thyroidal iodide uptake the drinking water of the mice was supplemented 
with 5 mg/ml L-T4 (Sigma-Aldrich). SMAD-NIS-MSCs were applied three times every 
second day via the tail vein at a concentration of 5 × 105 cells in 500µl PBS. 72 h after 
the last MSC application mice were injected intraperitoneally with 18.5 MBq (0.5 mCi) 
123I. The gamma camera was equipped with a low-energy high resolution collimator 
(e.cam, Siemens, Munich, Germany) and was used to measure radioiodide 
biodistribution. For the analysis of regions of interests (ROIs) HERMES GOLD 
(Hermes Medical Solutions, Stockholm, Sweden) software was used. Results are 
expressed as % ID/g. The radionuclide retention time was determined by serial 
scanning within the tumors. Dosimetric calculations were performed according to the 
concept of medical internal radiation dose using the dosis factor of RADARgroup 
(www.dosisinfo-radar.com).  
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Immunohistochemical staining  
After systemic SMAD-NIS-MSC administration and imaging studies, HCC xenografts 
or other organs (liver, lung and spleen) were dissected from all mice of the 123I-
scintigraphy study and tissues embedded in paraffin. Immunohistochemical NIS 
staining of paraffin-embedded tissue sections was performed as described previously 
[84]. Immunohistochemical staining of TGFB1 was performed on HuH7 tumors on a 
BenchMark XT automated stainer (Ventana, Tucson, AZ) with an antibody against 
TGFB (ab92486, abcam, Cambridge, UK) using the ultraVIEW DAB Detection Kit (all 
reagents from Ventana, Tucson, AZ). The tumor sections were deparaffinized with EZ 
Prep at 75°C and 76°C, heat pretreated in Cell Conditioning 1 (CC1) for antigen 
retrieval at 76°C – 100°C and then incubated with the primary antibody diluted in 
antibody diluent 1:150 for 32 min at 37°C after inactivation of the endogenous 
peroxidase using UV-inhibitor for 4 min at 37°C. The slides were incubated with a HRP 
Universal Multimer for 8 min. Antibody binding was detected using DAB as chromogen 
and counterstained with hematoxylin for 10 min with subsequent bluing in bluing 
reagent for 10 min. Afterwards, slides were manually dehydrated by washing with 
alcohol of increasing concentration (70%, 96%, 100%) and xylene, and coverslipped 
using Pertex® mounting medium (Histolab, Goeteborg, Sweden, 00801). 
 
Radioiodine therapy study  
Mice were treated 10-days before therapeutic application of radioiodide with 5 mg/ml 
L-T4 in their drinking water as described above. The therapy group received three 
SMAD-NIS-MSC injections on every second day (each 5 × 105 cells/500 µl PBS) 
followed by 55.5 MBq 131I 48 hours after the last SMAD-NIS-MSC injection (n=6; 
SMAD-NIS-MSCs + 131I). As a control, a subset of mice received saline (NaCl) instead 
of radioiodine (n=6; SMAD-NIS-MSCs + NaCl). 24 h after the 131I or NaCl application 
the treatment cycle was repeated. One additional MSC application followed by a third 
131I (55.5 MBq) or NaCl injection 48 hours later was done for therapy completion. A 
further control group was injected with NaCl only (n=5; NaCl + NaCl). Tumor volume 
was measured regularly and estimated as described above. Mice were euthanized 
when the tumor volume exceeded 1500 mm3. 
 
Indirect immunofluorescence assay 
Frozen tissue sections of tumors from the radioiodine therapy study were used for 
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indirect immunofluorescence analysis of Ki67 (cellular proliferation) and CD31 (blood 
vessel density) as described previously [60]. Identical conditions as for illumination, 
exposure time and system settings for digital image processing were used for capturing 
regions of the slides. The percentage of positive cells for Ki67 and areas for CD31 in 
the tumors was quantified by evaluation of 6 high-power fields per tumor using ImageJ 
software (NIH, Bethesda, MD). Results are presented as means ± SEM.  
 
Statistical methods 
Results are expressed as mean ± SEM, mean-fold change ± SEM or percentage. 
Statistical significance for in vitro experiments was tested by two-tailed Student´s t-
test. Statistical significance for in vivo experiments was perfomed by one-way ANOVA 
for tumor volumes and log-rank test for survival plots. P values of < 0.05 were 
considered significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
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4.4 Results 
 
SMAD-NIS-MSCs show enhanced NIS-mediated radioiodide accumulation 
following TGFB1 stimulation   
 
Radioiodide uptake assays revealed a 3.4 to 4.9 fold increase in NIS-mediated 
radioiodide uptake activity in MSCs stably transfected with the NIS gene under control 
of a SMAD-responsive promoter (SMAD-NIS-MSCs) after stimulation with TGFB1 (5-
25 ng/ml) (Fig. 1A). Stimulation with 5-15 ng/ml TGFB1 resulted in a dose dependent 
increase of radioiodide accumulation, which reached a plateau at higher doses of 
TGFB1 (20 or 25 ng/ml). NIS-specificity was confirmed using the NIS-specific inhibitor 
perchlorate, which blocked radioiodide uptake in all experiments (Fig. 1A). 
 
 
Fig. 1: Establishment of mesenchymal stem cells (MSCs) stably expressing NIS under control of a 
SMAD-responsive promoter. Iodide uptake studies revealed a 3.4 up to 4.9-fold high NIS-specific and 
perchlorate-sensitive 125I uptake in SMAD-NIS-MSCs stimulated with TGFB1 (5-25 ng/ml) as compared 
to unstimulated cells, where no radioiodide uptake above background levels was observed (A). 
Combined treatment of SMAD-NIS-MSCs with TGFB1 (10 ng/ml) and HuH7-CM led to further increased 
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radioiodide uptake as compared to stimulated cells without HuH7-CM (B). In contrast to that, a 
stimulation with MDA-MB 231-CM and TGFB1 did not result in a significant increase in radioiodide 
uptake activity of SMAD-NIS-MSCs (B). SMAD-NIS-MSCs were additionally transfected with constructs 
expressing SMAD3 (SMAD-NIS-MSCs + SMAD3), SMAD4 (SMAD-NIS-MSCs + SMAD4) or transfected 
with both expression constructs (SMAD-NIS-MSCs + SMAD3 + SMAD4) (C). Higher radioiodide uptake 
activity after TGFB1 (10 ng/ml) treatment was revealed in the presence of SMAD3, whereas it did not 
increase with higher expression levels of SMAD4. SMAD-NIS-MSCs expressing SMAD3 and SMAD4 
showed a radioiodide uptake higher than SMAD-NIS-MSCs and SMAD-NIS-MSCs + SMAD4, but was 
lower than SMAD-NIS-MSCs + SMAD3 after TGFB1 treatment (C). Data are represented as means of 
three independent experiments ± SEM (n=3; two-tailed Student’s t-test: *p<0.05; ** p <0.01, *** p 
<0.001). 
 
SMAD-NIS-MSCs were additionally stimulated by adding HCC (HuH7)-conditioned 
medium (CM) (Fig. 1B). Stimulation of SMAD-NIS-MSCs with both TGFB1 (10 ng/ml) 
and HuH7-CM resulted in a robust increase in radioiodide accumulation as compared 
to stimulation with TGFB1 alone. No radioiodide uptake activity was observed when 
SMAD-NIS-MSCs were exposed to HuH7-CM only (Fig. 1B). TGFB1 protein levels in 
HuH7-CM were analyzed by enzyme-linked immunosorbent assay (ELISA), which 
confirmed TGFB1 protein expression in HuH7 cells, but showed that HuH7-CM 
contains only inactive TGFB1 (data not shown). These findings correlate with the 
results shown above, where no radioiodide uptake is seen in SMAD-NIS-MSCs 
stimulated with HuH7-CM only. Additionally, to determine this effect is also seen with 
other tumor cells, SMAD-NIS-MSCs were treated with CM from MDA-MB 231 cells 
(human breast carcinoma cells) (Fig. 1B). Again, stimulation of SMAD-NIS-MSCs with 
MDA-MB 231-CM alone resulted in no radioiodide uptake activity. Further, only a slight 
increase of radioiodide uptake was observed after combined treatment with MDA-MB 
231-CM and TGFB1 which was not statistically significant. 
To further investigate activation of the promoter through TGFB1 (SMAD) signaling, 
variants of SMAD-NIS-MSCs where established by stably transfecting SMAD-NIS-
MSCs with SMAD3 or SMAD4 expression constructs (Fig. 1C). In SMAD-NIS-MSCs 
transfected with the SMAD3 expression vector (SMAD-NIS-MSCs + SMAD3) TGFB1 
stimulation (10 ng/ml) led to significantly increased NIS-mediated perchlorate-sensitive 
radioiodide uptake as compared to stimulated SMAD-NIS-MSCs. Transfection of 
SMAD-NIS-MSCs with a SMAD4 expression vector (SMAD-NIS-MSCs + SMAD4) 
resulted in no increase of radioiodide uptake activity upon TGFB1 stimulation as 
compared to stimulated SMAD-NIS-MSCs. Combination of SMAD3 and SMAD4 
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expression in SMAD-NIS-MSCs (SMAD-NIS-MSCs + SMAD3 + SMAD4) revealed an 
increase of radioiodide uptake after TGFB1 stimulation as compared to stimulated 
SMAD-NIS-MSCs and as compared to SMAD-NIS-MSCs + SMAD4, but a decrease 
as compared to TGFB1 stimulated SMAD-NIS-MSCs + SMAD3 (Fig. 1C). No 
radioiodide uptake activity above background levels was observed without TGFB1 
stimulation or upon treatment with perchlorate (Fig. 1C). 
 
Radioiodide biodistribution in vivo 
SMAD-NIS-MSCs (0.5 × 106) where injected intravenously via the tail vein into nude 
mice harboring subcutaneous HCC xenograft tumors, three times in 48 h intervals. 72 
h after the last MSC application, 18.5 MBq 123I were administered intraperitoneally. 
Radioiodide biodistribution monitored by 123I-scintigraphy (Fig. 2) revealed 
approximately 6.8 ± 0.8 % of the injected dose per gram (ID/g) radioiodide 
accumulation in tumors after SMAD-NIS-MSC application (Fig. 2A, C). A biological half-
life of 2.2 h and a tumor absorbed dose of 28.2 mGy/MBq was calculated for 131I. 
Endogenous NIS-mediated radioiodide uptake was observed in the stomach, salivary 
glands and thyroid gland. Radioiodide uptake in the urinary bladder is due to renal 
excretion of 123I (Fig. 2A). Injection of perchlorate 30 min prior to 123I administration 
resulted in blockage of radioiodide accumulation in tumors, stomach, salivary glands 
and thyroid gland (Fig. 2B).    
 
 
Fig. 2: 123I-scintigraphy showed high NIS-specific tumoral radioiodide uptake. Three systemic injections 
of SMAD-NIS-MSCs on every second day in mice harboring subcutaneous HuH7 tumors resulted in a 
maximum of approximately 6.8 % ID/g tumor (n=5) (A, C). Tumoral radioiodide uptake was blocked 
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upon treatment with the NIS-specific inhibitor perchlorate (n=1) (B). Data are represented as mean 
values ± SEM. 
 
NIS and TGFB1 protein expression in HuH7 tumors ex vivo 
To evaluate biodistribution of SMAD-NIS-MSCs ex vivo, NIS protein expression in 
resected tumors and non-target organs (liver, lung, spleen) was investigated by NIS-
immunohistochemistry (Fig. 3).  
 
 
Fig. 3: Tumor-specific NIS and TGFB1 protein expression. NIS-specific immunoreactivity was detected 
in all tumors of mice that received systemically applied SMAD-NIS-MSCs (A) as compared to non-target 
organs, where no NIS protein expression was detected (B-D). Further, TGFB1 protein expression was 
confirmed within subcutaneous HuH7 tumors and the tumor stroma (E). One representative image at 
20× magnification is shown each.  
 
Throughout the tumor stroma, NIS-specific immunoreactivity was detected in mice that 
were injected with SMAD-NIS-MSCs (Fig. 3A), whereas no NIS protein expression was 
observed in non-target organs (Fig. 3B-D). These data show efficient MSC recruitment 
into the tumor stroma after systemic application and activation of the SMAD-responsive 
promoter resulting in NIS protein expression.  
To confirm TGFB1 expression in subcutaneous HuH7 tumors, tumors were stained for 
TGFB1 protein expression, showing TGFB1 expression within tumor and its stroma 
(Fig. 3E). 
 
In vivo radioiodine therapy studies 
Therapeutic efficacy of 131I was evaluated using SMAD-NIS-MSCs in HuH7 tumors 
(Fig. 4). Animals of the therapy group received two cycles of three SMAD-NIS-MSC 
applications in 48 h intervals followed by a single 131I injection (55.5 MBq each) after 
the third MSC application.  
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Fig. 4: 131I therapy of subcutaneous HuH7 tumors led to a delay in tumor growth and improved survival. 
For an in vivo radionuclide therapy study, mice received three SMAD-NIS-MSC applications on every 
second day followed by 55.5 MBq 131I 48 h after the last MSC injection. For therapy end, a final cycle 
was done consisting of a single SMAD-NIS-MSC application and 131I injection 48 h afterwards (n=6; 
SMAD-NIS-MSC + 131I) (A). Therapy of mice harboring HuH7 tumors resulted in a significant delay in 
tumor growth as compared to controls receiving SMAD-NIS-MSCs and NaCl (n=6; SMAD-NIS-MSC + 
NaCl) or NaCl only (n=5; NaCl + NaCl) (A). Further, therapy led to an improved overall survival in therapy 
animals (B). 
 
For a third and last therapy round, a single SMAD-NIS-MSC application was given 
followed by a therapeutic dose of 131I. A significant delay in tumor growth was seen in 
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therapy mice treated with SMAD-NIS-MSCs followed by 131I application (SMAD-NIS-
MSCs + 131I) as compared to controls, which received either SMAD-NIS-MSCs 
followed by application of saline (NaCl) instead of 131I (SMAD-NIS-MSCs + NaCl) or 
NaCl only (NaCl + NaCl) (Fig. 4A). Both controls showed continuous exponential tumor 
growth (Fig. 4A). Analysis of survival revealed a maximum of 21-24 days for mice in 
control groups, whereas mice in therapy showed prolonged survival of up to 63 days 
(Fig. 4B). 
For a more detailed analysis, dissected tumors were stained for Ki67 (green; 
proliferation marker) and CD31 (red; marker for blood vessels) immunofluorescence 
(Fig. 5). Striking differences were seen between mice in therapy (SMAD-NIS-MSCs + 
131I) and mice in control groups (SMAD-NIS-MSCs + NaCl; NaCl + NaCl) (Fig. 5A). 
Tumors after 131I-therapy revealed a lower Ki67-index of 35.3 ± 5% and a mean blood 
vessel density of 1.4 ± 0.4%, whereas tumors of control groups showed a higher 
proliferation index of 52.9 ± 2.8% (SMAD-NIS-MSCs + NaCl) and 64.4 ± 4.2% (NaCl 
+ NaCl) and blood vessel density of 2.7 ± 0.5% (SMAD-NIS-MSCs + NaCl) and 2.2 ± 
0.2% (NaCl + NaCl) (Fig. 5B, C). 
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Fig. 5: Ki67 and CD31 immunofluorescence staining. Immunofluorescence analysis for Ki67 (green) 
and CD31 (red, labeling blood vessels) (A) showed significantly decreased proliferation (Ki67, 35.3 ± 
5 %) as well as reduced blood vessel density (CD31, 1.4 ± 0.4%) in resected tumors of mice treated 
with SMAD-NIS-MSC followed by 131I treatment as compared to tumors of mice injected with SMAD-
NIS-MSCs and NaCl (Ki67, 52.9 ± 2.8%; CD31, 2.7 ± 0.5%) or NaCl only (Ki67, 64.4 ± 4.2%; CD31, 2 
± 0.2%). Slides of tumors were counterstained with Hoechst nuclear stain. One representative image at 
20× magnification is shown each. 
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4.5 Discussion 
 
The theranostic NIS gene allows noninvasive imaging of functional NIS expression by 
123I-scintigraphy, thereby enabling tracking of gene delivery vehicles by radioiodide 
imaging, as well as application of 131I for a therapeutic purpose. Our laboratory and 
others have extensively investigated the capacity and efficacy of NIS gene transfer to 
induce radioiodide accumulation in non-thyroidal tumors using MSCs as NIS transgene 
delivery vehicles [56-60]. Earlier studies of active MSC engraftment in a HCC xenograft 
model using the constitutively active cytomegalovirus (CMV) promoter to express NIS 
in MSCs showed the proof-of-principle of active NIS-MSC tumor homing, followed by 
effective NIS expression in the tumor stroma and a significant delay in tumor growth 
after application of 131I [57]. Although these results were highly promising for a MSC-
based NIS-mediated radionuclide therapy approach in non-thyroidal tumors, using the 
non-selectively activated CMV-promoter involves the risk of potential side effects due 
to MSC recruitment to normal tissues in the process of normal tissue homeostasis. To 
reduce toxicity by undesired effects in non-target organs, further studies focused on 
restricting NIS expression to the tumor environment. Growing HCC tumors require an 
active tumor stroma consisting of various tumor stroma-specific cells such as cancer-
associated fibroblasts (CAFs) and inflammatory cells, but are also marked by high 
angiogenesis. The inflammatory response within the tumor leads to increased levels 
of various cytokines and chemokines [51, 58, 59, 113]. In previous studies from our 
group a RANTES/CCL5 promoter was used to drive NIS expression in MSCs thus 
enhancing tumor stroma-specificity in subcutaneous HCC xenografts as well as colon 
cancer liver metastases mouse models [58, 59]. The NIS-mediated therapy approach 
resulted in an improved therapeutic response in animals harboring subcutaneous HCC 
tumors, namely a significant delay in tumor growth and prolonged animal survival, as 
compared to the former study using a CMV-promoter for NIS transgene expression 
[57, 58]. The clinically more relevant question whether this therapy approach could 
also be used in metastatic disease was examined using a colon cancer liver 
metastases model, where similarly high therapeutic efficacy and improved survival was 
observed [59]. Further studies to limit activation of NIS transgene expression to the 
tumor environment of subcutaneous and orthotopic HCC xenografts have included 
targeting the tumor hypoxia response [60]. A synthetic HIF1α-responsive promoter was 
designed to activate NIS transgene expression as soon as MSCs encounter hypoxic 
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regions of solid tumors. Interestingly, systemic application of these HIF-NIS-MSCs 
followed by 131I injection resulted in a significant delay in tumor growth and prolonged 
animal survival only an orthotopic HCC model [60]. Although these approaches 
revealed promising therapeutic responses, our aim in the present study was to expand 
the individualized design of genetically engineered MSCs for NIS expression under 
control of promoters activated by micromileu-derived signals to enhance selectivity, 
effectiveness and flexibility of MSC-based NIS gene delivery, and in parallel, potentially 
addressing issues related to tumor heterogeneity. As interindividual and intraindividual 
tumor heterogeneity is an enormous challenge for successful cancer therapy, the 
search for tools for individualization of cancer treatment is critical for future 
personalized care of cancer patients. In this context, the growing knowledge of tumor 
stroma biology offers interesting strategies to tailor tumor stroma targeted therapy 
approaches. TGFB1 is known to be a central player in tumor biology, in particular tumor 
micromilieu-associated signaling, and has also been characterized to be significantly 
upregulated in HCC to promote tumorigenesis and exert immunosuppressive effects 
[114]. While at first TGFB1 is  expressed in the microenvironment of pre-malignant 
tumors to control tumor progression, its local expression is later required to promote 
tumor growth as well as metastasis [115]. Source of this cytokine is not only its 
expression in tumor cells but also in endothelial cells, fibroblasts, leucocytes, 
mesenchymal and myeloid precursor cells, among others, where it can act in a 
paracrine or autocrine manner [115].  
TGFB plays an important role for HCC treatment as higher levels of TGFB lead to 
resistance to anticancer treatments. As radiotherapy and chemotherapy can increase 
TGFB expression and activity, a combination with TGFB inhibitors is thought to 
enhance tumor sensitivity to those treatment strategies [102]. Further, TGFB is linked 
to hypoxia in terms of epithelial-mesenchymal transition (EMT) induction and VEGF 
signaling and a combination of TGFB inhibitors with anti-angiogenic or hypoxia-
induced treatment strategies might be an option as well [102]. Other than that, the high 
expression levels of TGFB1 in tumor cells and the tumor microenvironment makes 
TGFB1 signaling an interesting candidate to create novel promoters for tumor stroma 
targeted NIS expression in the context of NIS gene therapy. In the present study a 
TGFB1-inducible SMAD-responsive promoter, consisting of a 5× multimer of the SMAD 
binding site AGCCAGACAGT, was designed to drive transgene MSCs (referred to as 
SMAD-NIS-MSCs). In vitro analysis of SMAD-NIS-MSCs showed a robust dose-
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dependent NIS-mediated accumulation of radioiodide upon TGFB1 stimulation. 
Accumulation of radioiodide in SMAD-NIS-MSCs was further enhanced through 
combined stimulation with TGFB1 and HuH7-CM. This additive increase in radioiodide 
uptake activity appears to be dependent on the tumor line used, as treatment of SMAD-
NIS-MSCs with CM from MDA-MB 231 cells did not result in a significant increase in 
promoter activity. An explanation might be the presence of co-factors in CM, which 
trigger SMAD expression in MSCs and thus altering sensitivity for TGFB1. As HuH7-
CM only contained inactive TGFB1 protein, the exact mechanisms of the increased 
activity are not known yet and have to be further investigated in future studies.  
The canonical TGFB signaling pathway (SMAD dependent) is regulated by different 
SMAD proteins. After binding of active TGFB1 to the respective receptor, SMAD1, 2, 
3, 5 and 8 are phosphorylated and form complexes with the common mediator SMAD4 
[115]. Translocation of the SMAD complex into the cell nucleus leads to gene 
expression regulation. To understand the exact mechanisms of promoter activation of 
SMAD-NIS-MSCs in our study, SMAD-NIS-MSCs were additionally transfected with 
vectors expressing SMAD3 or SMAD4. These vectors are driven by the CMV-promoter 
and are thus permanently expressing SMAD3 or SMAD4. To investigate regulation of 
NIS expression, the additionally transfected SMAD-NIS-MSCs were tested by iodide 
uptake assay with or without TGFB1 stimulation. As TGFB signaling requires 
phosphorylated SMADs to become active, no radioiodide activity was observed in 
SMAD-NIS-MSCs, containing expression vectors for SMAD3 or SMAD4, in the 
absence of TGFB1 stimulation. Upon TGFB1 stimulation an enhanced NIS-mediated 
radioiodide uptake activity in the presence of SMAD3 was observed, whereas this 
effect was not observed by SMAD4, showing the influence of different SMADs on the 
SMAD-responsive promoter used to control NIS expression. The subsequent in vivo 
123I-scintigraphy studies showed the recruitment of SMAD-NIS-MSCs into the tumor 
environment of experimental HuH7 tumors and led to a robust tumor-selective TGFB1-
driven induction of the NIS transgene as shown by tumor-specific radioiodide 
accumulation.   
NIS expression within the tumors was further confirmed by NIS immunoreactivity, 
which demonstrated high NIS protein expression within tumors but not in non-target 
organs such as liver, lung or spleen. Further, TGFB1 immunohistochemistry confirmed 
expression of TGFB1 within the experimental HuH7 tumors. SMAD-NIS-MSCs were 
then applied followed by therapeutic application of 131I which resulted in a significant 
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reduction in tumor growth and prolonged survival. Although the calculated biological 
half-life of 2.2 h and tumor-absorbed dose of 28.2 mGy/MBq/g tumor was lower than 
those observed in previous studies, the therapy study revealed as strong a therapeutic 
effect comparable to our previous studies using the specific RANTES/CCL5 promoter 
[58]. 
The use of traditional anticancer therapies, such as radiation treatment or 
chemotherapy, demonstrated an induction of TGFB1 expression. Biswas et al. 
illustrated enhanced levels of circulating TGFB1 in plasma after thoracic irradiation or 
chemotherapy (doxorubicin) in mice with mammary carcinoma [116]. Further, as shown 
by our group (unpublished data) and others, external beam radiation therapy of tumors 
is able to induce an enhanced inflammatory response resulting in increased secretion 
of diverse growth factors and chemokines, including TGFB1, which in turn also led to 
an enhanced recruitment of MSCs [64, 65, 117]. Therefore, the approach outlined in 
the present study based on NIS gene expression driven by a TGFB1-inducible SMAD-
responsive promoter opens the prospect of combination with conventional therapies, 
such as external beam radiation or chemotherapy, to take advantage of synergistic 
effects thereby fostering TGFB1-induced tumoral NIS expression and improving 
therapeutic efficacy of MSC-based NIS-induced radioiodide therapy. The results 
presented here build on previous studies, including the initial clinical trials of 
engineered MSCs for tumor therapy, by providing new targeting approaches that could 
expand targeting options in the next generation of engineered anti-tumor MSCs.  
Taken together, our study demonstrates high tumor stromal recruitment of SMAD-
NIS-MSCs and a robust, biologically targeted NIS transgene expression in 
subcutaneous HuH7 tumors through TGFB1-induced SMAD promoter activity. After 
systemic application of SMAD-NIS-MSCs followed by 131I injection, a significant 
therapeutic effect was observed, resulting in reduction of tumor growth and improved 
survival. The proof-of-principle in this study opens the exciting prospect for future 
studies, where we will build on the presented results to investigate the enormous 
potential of TGFB1-induced promoters for NIS transgene expression for an improved 
and novel theranostic NIS gene approach. As native gene promoters are generally 
more efficient than the synthetic promoters used in this study as a proof of concept, in 
future studies it will be important to identify efficient TGFB1-regulated native promoters 
that may allow a more robust level of transgene induction in the context of the tumor 
environment. 
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5.1 Abstract 
 
The tumor-homing properties of mesenchymal stem cells (MSC) have led to their 
development as delivery vehicles for the targeted delivery of therapeutic genes such 
as the sodium iodide symporter (NIS) to solid tumors. External beam radiation therapy 
(EBRT) may represent an ideal setting for the application of engineered MSC-based 
gene therapy as tumor irradiation may enhance MSC recruitment into irradiated tumors 
through the increased production of select factors linked to MSC migration. In the 
present study, the irradiation of human liver cancer cells (HuH7) (1-10 Gy) showed a 
strong dose-dependent increase in steady state mRNA levels of CXCL8, 
CXCL12/SDF-1, FGF2, PDGFβ, TGFB1, TSP-1 and VEGF (0-48 h), which was verified 
for most factors at the protein level (after 48 h). Radiation effects on directed MSC 
migration was tested in vitro using a live cell tracking migration assay and supernatants 
from control and irradiated HuH7 cells. A robust increase in mean forward migration 
index (yFMI), mean center of mass (yCoM) and mean directionality of MSCs towards 
supernatants was seen from irradiated as compared to nonirradiated tumor cells. 
Transferability of this effect to other tumor sources was demonstrated using the human 
breast adenocarcinoma cell line (MDA-MB-231), which showed a similar behavior to 
radiation as seen with HuH7 cells in qPCR and migration assay. To evaluate this in a 
more physiologic in vivo setting, subcutaneously growing HuH7 xenograft tumors were 
irradiated with 0, 2 or 5 Gy followed by CMV-NIS-MSC application 24 h later. Tumoral 
iodide uptake was monitored using 123I-scintigraphy. The results showed increased 
tumor-specific dose-dependent accumulation of radioiodide in irradiated tumors. Our 
results demonstrate that EBRT enhances the migratory capacity of MSCs and may 
thus increase the therapeutic efficacy of MSC-mediated NIS radionuclide therapy. 
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5.2 Introduction 
 
The sodium iodide symporter (NIS) is an intrinsic transmembrane glycoprotein with 13 
putative transmembrane domains. NIS mediates the active uptake of iodide into the 
thyroid gland and as such, has formed the basis for the diagnostic and therapeutic 
application of radioiodine in benign and especially malignant thyroid diseases for 
almost 70 years [20]. Its properties as a reporter and therapy gene allows noninvasive 
imaging of functional NIS expression by 123I-scintigraphy and 124I-PET imaging and 
robust therapeutic effects by the application of 131I and related radionuclides [20-23]. 
The extensive clinical experience derived from work with NIS-biology and NIS-
mediated radioiodine accumulation in diagnosis and imaging of differentiated thyroid 
cancer has allowed expansion of this effective theranostic strategy to non-thyroidal 
tumor settings through the use of various delivery vehicles for tumor-targeted NIS gene 
expression. The approaches under evaluation include viral and non-viral vectors such 
as genetically engineered mesenchymal stem cells (MSC). The results to date have 
demonstrated tumor-selective NIS-mediated radioiodine accumulation leading to 
decreased tumor growth and prolonged survival of treated animals [28, 30, 33, 34, 36-
38, 41, 56-60, 96-99, 101]. MSCs are very promising potential vehicles for the delivery 
of therapeutic genes to tumors, as solid tumors are thought to have many of the 
characteristics of chronic wounds due to ongoing and extensive hypoxia, necrosis and 
angiogenesis, which drive MSC recruitment [45, 46]. The enhanced production of 
inflammatory cytokines, growth factors and chemokines by the tumor cells is thought 
to underlie the directed migration of MSCs to solid tumors. Previous reports have 
suggested that platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and the chemokine (C-
X-C motif) ligand 12/stromal cell-derived factor 1 (CXCL12/SDF-1) play important roles 
in the recruitment of MSCs into tumors environments.[5] Tumor external beam 
irradiation may represent a promising tool to enhance MSC homing to tumor 
microenvironments based on the localized tissue damage seen with irradiation leading 
to the increased secretion of inflammatory chemokines and growth factors [64, 65].  
In the present study we sought to evaluate the effect of external beam radiation on 
tumor-homing of adoptively applied engineered MSCs to determine if this treatment 
would improve or enhance functional MSC-mediated NIS gene expression within the 
experimental tumors. To this end, we investigated the effect of radiation on the 
  Chapter 3 
 
64 
 
chemokine and growth factor expression profile of the human hepatocellular carcinoma 
(HCC) cell line HuH7, as well as of the human breast adenocarcinoma cell line MDA-
MB-231, and the overall effect on the directed migration of MSC. The in vitro results 
where then validated in a HCC xenograft mouse model taking advantage of the 
reporter gene function of NIS. 
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5.3 Materials and methods  
 
Cell culture 
The human hepatocellular carcinoma cell line HuH7 was purchased from JCRB Cell 
Bank (JCRB 0403, Osaka, Japan) and cultured in DMEM (Sigma-Aldrich, St. Louis, 
Missouri, USA) supplemented with 10% FBS (Biochrom/Merck Millipore, Berlin, 
Germany) and 100 U/ml penicillin/100 µg/ml streptomycin (Sigma-Aldrich). The human 
breast adenocarcinoma cell line MDA-MB-231 was cultured in RPMI (Sigma_Aldrich), 
supplemented with 10% FBS and 100 U/ml penicillin/100 µg/ml streptomycin. A 
previously established, SV40 large T antigen immortalized MSC cell line derived from 
human bone marrow [111], was cultured in RPMI supplemented with 10% FBS and 
100 U/ml penicillin/100 µg/ml streptomycin. Primary human bone marrow-derived CD-
34-negative MSCs were cultured as described previously [112]. Cells were maintained 
at 37°C and 5% CO2 in an incubator.  
 
Stable transfection and establishment of MSCs  
The establishment of wild type MSCs (WT-MSC) transfected with the  
expression vector CMV-NIS-pcDNA3 (full length NIS cDNA coupled to the 
cytomegalovirus (CMV) promoter) and the resulting stably transfected cell line (CMV-
NIS-MSC) was described previously [57].   
 
125I uptake assay 
Radioiodide uptake of CMV-NIS-MSC was determined at steady-state conditions 
before in vivo application as described previously by Spitzweg et al. [66]. Results were 
normalized to cell survival measured by cell viability assay (see below). 
 
Cell viability assay 
Cell viability was determined as described previously [60].  
 
Irradiation of HuH7 and MDA-MB-231 cells 
1×106 HuH7 or MDA-MB-231 cells, respectively, were seeded on 100 mm3 surface cell 
culture plates. 12 h before radiation, cells were switched to serum-free medium. Tumor 
cells were irradiated with doses from 0 to 10 Gray (Gy) using an Xstrahl cabinet 
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Irradiator RS225 (200 kV, 10 mA, Thoraeus filter, 1 Gy in 1 min 3s; Xstrahl LTD, 
Camberley, Surray, England). 
 
Quantitative real-time PCR (qRT-PCR) 
Total RNA from HuH7 cells was extracted after 4, 8, 12, 24 and 48 h post radiation (0-
10 Gy respectively) using the RNeasy Mini Kit with QIAshredder (Qiagen, Hilden, 
Germany). The same procedure was performed for MDA-MB-231 cells after 8, 24 and 
48 h post radiation. Reverse transcription and quantitative real-time PCR were 
conducted as previously described using a Mastercycler ep gradientS PCR cycler 
(Eppendorf, Hamburg, Germany) [58]. The following primers were used: ACTB (β-
actin): Forward primer (5′-AGAAAATCTGGCACCACACC-3′) and reverse primer (5′-
TAGCACAGCCTGGATAGCAA-3′), CXCL8: Forward primer (5′-
TCTGCAGCTCTGTGTGAAGG-3′) and reverse primer 
(5′-TTCTCCACAACCCTCTGCAC-3′), CXCL12/SDF-1: Forward primer 
(5′-AGAGCCAACGTCAAGCATCT-3′) and reverse primer (5′-
TAGCACAGCCTGGATAGCAA-3′), FGF2: Forward primer 
(5′-GGAGAAGAGCGACCCTCAC-3′) and reverse primer 
(5′-AGCCAGGTAACGGTTAGCAC-3′), PDGFB: Forward primer 
(5′-TTGGCTCGTGGAAGAAGG-3′) and reverse primer (5′-
CGTTGGTGCGGTCTATGA-3′), TGFB1: Forward primer 
(5′-CAGCACGTGGAGCTGTACC-3′) and reverse primer 
(5′-AAGATAACCACTCTGGCGAGTC-3′), THBS1 (TSP1): Forward primer 
(5′-TTGTCTTTGGAACCACACCA-3′) and reverse primer 
(5′-CTGGACAGCTCATCACAGGA-3′), VEGF: Forward primer 
(5′-CTACCTCCACCATGCCAAGT-3′) and reverse primer 
(5′-ATGATTCTGCCCTCCTCCTT-3′). Relative expression levels were calculated from 
ΔΔCt values normalized to internal β-actin. Results are expressed as fold change 
relative to controls.   
 
Enzyme-linked Immunosorbent Assay (ELISA)  
Supernatant from untreated and irradiated HuH7 cells was removed after 4, 8, 12, 24 
or 48 h, centrifuged and stored at -80°C. ELISA assays for CXCL8, CXCL12/SDF-1, 
FGF2, PDGF beta homodimer (PDGF BB), TGF-β1, TSP1 and VEGF were performed 
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using the respective DuoSet ELISA kit (R&D Systems, Abington, UK) following the 
manufacturer’s instructions. Results are expressed as fold change relative to controls. 
 
Cell Migration Assay 
Chemotaxis of MSCs in relation to a gradient between irradiated and non-irradiated 
supernatants of HuH7 or MDA-MB-231 cells (48 h post radiation respectively) was 
tested using a live cell tracking migration assay (IBIDI µ-slide Chemotaxis; Martinsried, 
Germany) used according to the manufacturer’s directions. After seeding of 0.3×106 
MSC/ml in collagen, MSCs were exposed to a gradient between supernatants of non- 
and irradiated HuH7 or MDA-MB-231 cells. Monitoring of chemotaxis and tracking of 
twenty randomly selected cells was done as previously described [68]. For 
quantification of the migratory behavior of MSCs, the forward migration index (FMI), 
the center-of-mass (CoM) and directness were calculated, reflecting the distance and 
directness of migration for all tracked cells.  
 
Animals 
Five-week-old female CD1 nu/nu mice from Charles River (Sulzfeld, Germany) were 
housed under specific pathogen-free conditions with access to mouse chow and water 
ad libitum and were allowed to acclimatize for 1 week before tumor cell implantation. 
The experimental protocol was approved by the regional governmental commission for 
animals (Regierung von Oberbayern) and experiments were performed in accordance 
with institutional guidelines of the Klinikum rechts der Isar, Technische Universität 
München. 
 
HuH7 xenograft tumors 
HuH7 xenograft tumors were established by subcutaneous injection of 5×106 HuH7 
cells in 100 µl PBS into the flank region as described previously [57]. Tumor volumes, 
which were regularly measured, were estimated using the equation: length × width × 
height × 0.52 and animals were sacrificed when tumors exceeded a size of 1500 mm3. 
 
Irradiation of HCC xenografts 
Experiments were initiated when the tumors had reached a diameter of approximately 
5-10 mm. The irradiation was performed using the high precision image-guided small 
animal radiation research platform (SARRP, X-Strahl, West Midlands, UK). Mice were 
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anaesthetized by isoflurane/oxygen inhalation for the duration of each treatment. 
Cone-beam computed tomography (CBCT) using 60 kV and 0.8 mA photons was 
performed for each mouse to visualize the subcutaneous tumors. All tumors were 
irradiated using 220 kV and 13 mA x-ray beams using a 3×9 mm2, 5×5 mm2 or 10×10 
mm2 collimator. The central axis of the beams was set in the isocenter of the tumor 
with a mean irradiation dose of 2 or 5 Gy. The SARRP control software and Muriplan 
were used to precisely target tumors and irradiation doses.  
 
MSC application and 123I-scintigraphy  
Mice were given 5 mg/ml L-T4 (Sigma-Aldrich) in their drinking water, to suppress 
thyroidal iodide uptake. CMV-NIS-MSCs were applied once via the tail vein at a 
concentration of 5×105 cells/500µl PBS 24 h post tumor radiation. 72 h after MSC 
application mice received 18.5 MBq (0.5 mCi) 123I i.p. and radioiodide biodistribution 
was assessed using a gamma camera provided with a low-energy high resolution 
collimator (e.cam, Siemens, Munich, Germany). Regions of interest were analyzed 
using HERMES GOLD (Hermes Medical Solustions, Stockholm, Sweden), quantified 
and results expressed as a fraction of the total amount of applied radionuclide per gram 
tumor tissue (% ID/g). The radionuclide retention time was determined as described 
previously [60].  
 
Immunohistochemical NIS staining  
Immunohistochemical NIS staining of paraffin-embedded tissue sections derived from 
HCC xenografts or other organs (liver, lung and spleen) after systemic CMV-NIS-MSCs 
administration was performed as described previously [84]. 
 
Statistical methods 
Results are expressed as mean ± SEM or mean-fold change ± SEM and statistical 
significance was tested by two-tailed Student´s t-test, where p values < 0.05 were 
considered significant (*p < 0.05; **p < 0.01; ***p < 0.001). For migration assays, 
results are shown by Rayleigh test, where p values < 0.05 were considered significant 
(*p < 0.05; **p < 0.01; ***p < 0.001). 
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5.4 Results 
 
Irradiated HuH7 cells show increased expression of chemokines and growth 
factors implicated in MSC migration 
Tumor irradiation is thought to increase the expression of diverse chemokines and 
growth factors, many of which have been implicated in directed migration of MSCs. To 
study this in detail, HuH7 cells were evaluated for their steady state mRNA expression 
of CXCL8, CXCL12/SDF-1, PDGFB, FGF2, TGFB1, TSP1 and VEGF using qRT-PCR. 
Upon irradiation, the mRNA expression for each of these factors was increased as 
compared to nonirradiated cells, but the time course and response to radiation levels 
varied among the genes tested (Fig.1). The in vitro irradiation (1-10 Gy) of HuH7 cells 
did not result in a change in cell viability as compared to nonirradiated cells during 0-
48 h (data not shown). For radiation with 0, 2 and 5 Gy (as used in vivo), HuH7 cell 
viability was examined later time points, such as 5 or 7 days, and no decrease in cell 
viability was seen except after 5 days using 5 Gy, where a decrease of 18 % was seen 
(data not shown). 
Changes in mRNA levels were observed as early as 4 h post radiation treatment for all 
factors, with some of them increasing in a radiation dose-dependent manner (CXCL8, 
PDGFB, TGFB1 and TSP-1) (Fig. 1A, C, E, F). A peak in mRNA levels after irradiation 
was observed at 12 h for CXCL8 and FGF2, which was also dose-dependent, whereas 
a dose-dependent peak in CXCL12/SDF-1 and TSP-1 mRNA expression was seen at 
24 h (Fig. 1A, B, D, F). The maximum dose-dependent increase in PDGFB, TGFB1 
and VEGF mRNA expression was seen similarly at 12 h and 24 h post irradiation (Fig. 
1C, E, G). An effect of radiation on the steady state mRNA expression of CXCL12/SDF-
1, PDGFB and TSP-1 was observed up to 48 h (Fig. 1B, C, F).  
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Fig. 1: Gene expression of inflammatory cytokines and growth factors is enhanced by irradiation of 
HuH7 cells (1-10 Gy) during a period of 4 to 48 h (A-G). Data are represented as mean fold change ± 
SEM as compared to nonirradiated control cells (n=3; two-tailed Student’s t-test: *P<0.05; **P<0.01, 
***P<0.001). 
 
Effects seen on the mRNA level were then confirmed by ELISA (CXCL8, 
CXCL12/SDF-1, TGFB1, TSP-1 and VEGF) (Fig. 2). Protein levels for FGF2 and 
PDGFB remained below the detection limit of the ELISA kits. No increase in protein 
secretion was detected from 4-24 h post radiation (data not shown). CXCL8, 
CXCL12/SDF-1 and TGFB1 secretion showed a strong increase 48h after the 
irradiation of HuH7 cells, that also occurred in a dose-dependent manner with peak 
production seen at 4-5 Gy (Fig. 2A-C), whereas only a marginal increase of TSP-1 and 
VEGF was observed (Fig. 2D, E). Significant secretion of CXCL8 protein was observed 
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after irradiation with 8 or 10 Gy and of CXCL12/SDF-1 when using 2 Gy (Fig. 2A, B). 
Irradiation of HuH7cells with 4 Gy showed a significant increase in TGFB1 protein 
secretion (Fig. 2 C). 
 
 
Fig. 2: Protein secretion was assessed by ELISA and showed enhanced secretion of CXCL8, 
CXCL12/SDF-1, TGFB1, TSP-1 and VEGF 48 h post irradiation of HuH7 cells (1-10 Gy) (A-E). Data are 
represented as mean fold change ± SEM as compared to nonirradiated control cells (n=3; two-tailed 
Student’s t-test: *P<0.05; **P<0.01, ***P<0.001). 
 
MSCs exposed to irradiated HuH7 supernatant show enhanced directed 
migration  
Based on the results detailed above, it is clear that a complex set of factors linked to 
MSC recruitment are induced in the tumor line in response to external beam radiation. 
To functionally validate the effect of HuH7 irradiation on the directed migration of 
MSCs, a commercial 2D migration chamber and pseudo video imaging was applied. 
MSCs were subjected to a gradient generated between supernatants derived from 
nonirradiated and irradiated HuH7 cells, and the migratory behavior of individual cells 
was monitored over a 24 h period (Fig. 3). MSCs showed enhanced and directed 
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chemotaxis towards the irradiated supernatants. The analysis revealed a robust 
increase of mean forward migration index (yFMI), mean center of mass (yCoM) and 
mean directionality of MSCs towards supernatants from irradiated as compared to 
nonirradiated tumor cells (Fig. 3I-K). Enhanced MSC migration towards the 
supernatant isolated from irradiated cells was seen at 4 Gy (yFMI: 0.115±0.015; 
Rayleigh values p<0.05, yCoM: 94.42±3.19 µm) (Fig. 3E, I-J), 5 Gy (yFMI: 
0.105±0.026; Rayleigh values p<0.05, yCoM: 73.67±12.69 µm) (Fig. 3F, I-J) and 10 
Gy (yFMI: 0.105±0.005; Rayleigh values p<0.05, yCoM: 103.02±4.57 µm) (Fig. 3H, I-
J) as compared to controls. MSCs that were subjected to medium and supernatant 
from untreated HuH7 cells (yFMI: -0.01±0.025, yCoM: -9.04±15.07 µm) (Fig. 3A, I-J) 
or to supernatant from untreated HuH7 cells in both chambers (yFMI: 0.055±0.03, 
yCoM: 46.94 ±20.64 µm) (Fig. 3B, I-J) showed random chemokinesis, but no directed 
migration. 
 
Fig. 3: MSCs subjected to a gradient of isolated supernatants from nonirradiated and irradiated HuH7 
cells (1-10 Gy) showed enhanced direct migration over 24 h (C-H) as compared to untreated HuH7 cells 
as controls, where only random chemokinesis was observed (A-B). One representative image each is 
shown from two independent experiments. This was confirmed by quantification of chemotaxis 
  Chapter 3 
 
73 
 
parameters as yFMI, yCoM and directionality (I-K). yCoM is indicated by red dots (J). Data are 
represented as mean fold change ± SEM from two independent experiments. 
 
This was further confirmed by testing primary MSCs, which were subjected to 
untreated supernatants from HuH7 cells and from cells, which were irradiated with 0, 
1, 5 or 10 Gy (Fig. 4). Primary human bone marrow derived MSCs showed similar 
migratory behavior as seen in the immortalized MSCs (Fig. 3 and 4). 
 
 
Fig. 4: Chemotactic behavior of MSCs was further confirmed using primary human bone marrow derived 
MSCs (A-H). Primary MSCs migrated along a gradient of supernatants from nonirradiated to irradiated 
HuH7 cells (1, 5 and 10 Gy) over 24 h (C-E) as compared to controls (A-B). This was confirmed by 
quantification of chemotaxis parameters as yFMI, yCoM (red dots) and directionality (F-H). Data are 
represented as mean fold change ± SEM from two independent experiments. 
 
Irradiation of MDA-MB-231 cells leads to enhanced chemokine and growth factor 
expression as well as directed MSC migration to cell supernatants 
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To demonstrate that the effects of irradiation on human tumor cells is not only seen in 
HuH7 cells but also in other cancer cell lines, the human breast adenocarcinoma cell 
line MDA-MB-231 was irradiated in vitro using 0, 2, 5 or 10 Gy and mRNA expression 
was tested 0, 8, 24 and 48 h post radiation (Supplementary Fig. 1). MDA-MB-231 cells 
were evaluated for their steady state mRNA expression of CXCL8, CXCL12/SDF-1, 
TGFB1, TSP-1 and VEGF using qRT-PCR (Supplementary Fig. 1A-D). The mRNA 
expression for CXCL8, TGFB1, TSP-1 and VEGF was enhanced after radiation as 
compared to nonirradiated cells, but a variation in time course and response to 
radiation levels among the genes was observed (Supplementary Fig. 1A-D). No 
CXCL12/SDF-1 mRNA levels were detectable in MDA-MB-231 cells. CXCL8 mRNA 
expression levels showed a dose-dependent peak at 8 h but no increase at later time 
points (Supplementary Fig. 1A), whereas TGFB1 and VEGF mRNA expression 
showed a dose-dependent increase with a maximum at 24 h (Supplementary Fig. 1B, 
D). TSP-1 mRNA expression showed a dose-dependent increase with a maximum at 
24 and 48 h post irradiation (Supplementary Fig. 1C).  
To functionally validate the effect of MDA-MB-231 irradiation on the directed migration 
of MSCs, MSCs were subjected to a gradient generated between supernatants derived 
from nonirradiated and irradiated MDA-MB-231 cells as described above 
(Supplementary Fig. 2). Similar to the effects seen above with supernatants from HuH7 
cells, MSCs showed directed chemotaxis towards irradiated supernatants. An increase 
of mean forward migration index (yFMI), mean center of mass (yCoM) and mean 
directionality of MSCs towards supernatants from irradiated as compared to 
nonirradiated MDA-MB-231 cells was observed (Supplementary Fig. 2F-H). While 
there was only a minor effect observed using 2 Gy and 10 Gy (Supplementary Fig. 2C, 
E, F-H), clearly enhanced MSC migration towards the supernatant isolated from 5 Gy 
irradiated cells was observed (yFMI: 0.121±0.036; Rayleigh values p<0.01, yCoM: 
66.04±23.93 µm) (Supplementary Fig. 2D, F-H) as compared to controls 
(Supplementary Fig. 2A, B, F-H). Controls, in which MSCs were subjected to medium 
and supernatant from untreated MDA-MB-231 cells (yFMI: -0.061±0.012 yCoM: 
34.02±0.78 µm) (Supplementary Fig. 2A, F-H) or to supernatant from untreated MDA-
MB-231 cells in both chambers (yFMI: -0.01±0.01, yCoM: -0.28±0.21 µm) 
(Supplementary Fig. 2B, F-H), only showed random chemokinesis. 
 
Radiation pretreatment of tumors enhances MSC recruitment in vivo 
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To validate radiation enhanced MSC recruitment in an in vivo setting, subcutaneous 
HCC xenograft tumors implanted in nude mice were irradiated with 0, 2 or 5 Gy before 
systemic application of NIS-reporter engineered MSCs (Fig. 5). Using high precision 
image-guided SARRP, local tumor irradiation with CT guided imaging was performed 
(Fig. 5C). Isocenters were set in the tumor image to locate beams and calculate dose 
volume distribution within the tumors (Fig. 5A, C).   
 
Fig. 5: Irradiation was performed using SARRP. Upon radiation with 2 or 5 Gy, a CT was done allowing 
to mark and define the tumor (blue) (A). CTs are shown in transversal, sagittal and frontal orientation 
(C). Isocenters were set to locate the beams and to calculate the dose distribution within the tumor (A, 
B). One representative image is shown from a subcutaneous HuH7 xenograft tumor irradiated with 5 
Gy. 
 
After one i.v. injection of CMV-NIS-MSCs 24 h post radiation, MSC-mediated delivery 
of NIS expression into tumors was monitored by NIS reporter gene imaging using 123I-
scintigraphy (Fig. 6). Imaging studies revealed a significant tumor-specific 
accumulation of 7.9 ± 1.4 % and 9.2 ± 1.5 % of the total amount of applied 123I dose 
per gram tumor (ID/g) in tumors pretreated with 2 or 5 Gy, respectively, as compared 
to 5.3 ± 0.8 % ID/g in nonirradiated tumors (Fig. 6A-D). A tumor-absorbed dose of 17.4 
(nonirradiated), 27.6 (2 Gy) and 64.4 (5 Gy) mGy/MBq/g tumor 131I with an effective 
half-life of 2.7 (nonirradiated), 2.3 (2 Gy) and 2.5 (5 Gy) h was determined. 
Endogenous NIS expression was also seen in the thyroid gland, the salivary glands 
(SG) as well as in the stomach and, due to renal excretion of radioiodide, in the urinary 
bladder (Fig. 6A-C).  
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Fig. 6: 1 h after radioiodide injection, 123I-scintigraphy (A-D) demonstrated enhanced radioiodide 
accumulation in radiation pretreated subcutaneous HCC tumors followed by systemic CMV-NIS-MSC 
application (n=4, each group). One representative image is shown per group (A-C). Time course of 
radioiodide accumulation in tumors was determined by serial scanning (D). Nonirradiated tumors 
showed a maximum 123I uptake of 5.3 ± 0.8 % ID/g, whereas irradiated tumors revealed an accumulation 
of radioiodide up to 7.9 ± 1.4 % ID/g using 2 Gy or 9.2 ± 1.5 % ID/g using 5 Gy (D). Results are 
respresented as mean ± SEM. 
  
After 123I-scintigraphy, tissue sections of the tumors and non-target organs (liver, lung 
and spleen) were stained for NIS protein expression to determine the presence of 
MSCs by MSC-mediated NIS expression (Fig. 7). Nonirradiated tumors revealed only 
weak NIS expression in the tumors (Fig. 7A), whereas a pretreatment with 2 or 5 Gy 
led to higher levels of NIS expression, confirming a higher recruitment of MSCs to 
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irradiated tumors (Fig. 7E, I). No staining was observed in non-target organs (Fig. 7B-
D, F-H, J-L). 
 
Fig. 7: Compared to nonirradiated tumors (A), higher NIS-specific immunoreactivity (red) was detected 
in tumors pretreated with external beam radiation therapy upon systemic MSC application (E, I). For 
non-target organs, no NIS expression was detected (B-D, F-H, J-L). One representative image is shown 
each. Scale bar = 50 µm. 
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5.5 Discussion 
 
Mesenchymal stem cells (MSCs) are currently under evaluation as tumor delivery 
vehicles based in part on their excellent tumor-homing properties. An important issue 
in the further development of this strategy is how well it could work when used in 
combination with existing tumor therapy. External beam radiotherapy is the most 
common form of cancer radiotherapy in use today. In the present study, we sought to 
evaluate the potential effects of radiation on the ability of MSCs, engineered to express 
the reporter gene NIS, to invade experimental tumors. The mechanisms underlying 
MSC recruitment to tumors have not been fully elucidated. The process is thought to 
mirror the mechanisms that are used by leukocytes during their recruitment to inflamed 
tissues, utilizing a cascade of events driven by cytokines, chemokines, integrins and 
selectins. A group of factors including PDGFB, VEGF and FGF2, 
chemokines/cytokines such as CXCL8 and CXCL12/SDF-1 and the pleotropic growth 
factor TGFB1/3 among others have been linked to MSC migration [47]. The homing of 
MSCs to tumor tissue can in some instances be enhanced by external beam radiation 
tumor pretreatment, potentially through increased secretion of chemokines and growth 
factors resulting from radiation injury [47]. Previous studies by Klopp et al. have shown 
improved engraftment of adoptively applied MSCs to irradiated murine mammary 
carcinoma as compared to nonirradiated tumors [65]. Similar results were also 
demonstrated in gliomas using hematopoietic progenitor cells (HPC), where increased 
migration was documented after gliomas were irradiated [118].  
To test enhanced MSC homing following radiation treatment in a model of human 
hepatocellular cancer (HCC), we first addressed the question as to whether the 
expression and secretion of factors involved in the regulation of MSC migration were 
increased in the HCC cell line HuH7 following treatment [113, 114, 119]. The response 
to radiation differed between the genes tested with regards to level, time course and 
general response to radiation. The pleotropic cytokine TGFB1 is expressed in HCC 
and has been shown to promote tumorigenesis in established HCC tumors and to have 
an immunosuppressive effect [114]. In our study, irradiation of HuH7 cells revealed a 
dose-dependent increase in TGFB1 mRNA expression as well as enhanced protein 
secretion, though a slight decline in expression was observed when using high 
radiation doses (8 or 10 Gy). A similar effect was observed for VEGF, a central 
regulator of angiogenesis [114]. Irradiated HuH7 cells also showed an increase in 
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expression of another angiogenic factor, PDGFB. At the mRNA level, the highest 
increase was observed 12 h post radiation treatment, however PDGF-BB protein 
remained under the detection limit. Similar results were described in previous studies 
by Klopp et al., where a dose-dependent increase of TGFB1, PDGF-BB and VEGF 
protein expression was observed over a period of 48 h, when a murine mammary 
carcinoma cell line (4T1 cells) was irradiated with 0, 1 or 2 Gy [65]. In the HuH7 cell 
line, protein expression was not influenced by radiation before 48 h, whereas changes 
at the mRNA level appeared by 4 h post radiation treatment. In addition, we 
investigated FGF2, which is also known as a central regulator of the migratory potential 
of human MSCs [120]. Analysis of FGF2 revealed an increase on the mRNA level 
similar to PDGFB gene expression but remained below the detection limit for protein 
expression of irradiated HuH7 cells. Further investigation of the effect of radiation on 
HuH7 cells showed an increase of TSP-1 and the potent pro-inflammatory chemokines 
CXCL8 and CXCL12/SDF-1 on the mRNA and protein level. We observed an early 
effect of HuH7 cell radiation at the level of mRNA, where a wide range of chemokines 
and growth factors were increased as early as 4 h after irradiation and remained 
elevated until 24 h to 48 h post radiation treatment and for most factors an increase in 
protein secretion after 48 h. Thus, our data clearly demonstrate the ability of HuH7 
cells to increase their expression of cytokines and growth factors directly involved in 
MSC recruitment after radiation treatment. These findings were further confirmed in 
another human cancer cell line derived from breast adenocarcinoma (MDA-MB-231). 
MDA-MB-231 showed a similar response to radiation as HuH7 by increasing mRNA 
expression levels of CXCL8, TGFB1, TSP-1 and VEGF in a dose-dependent manner 
using 0,2 ,5 or 10 Gy, but differed in regard to mRNA levels and time course (0, 8, 24 
or 48 h).   
An in vitro migration assay was then performed to corroborate that irradiation of tumor 
cells can cause an increased migration of MSCs. Those experiments confirmed 
enhanced direct chemotaxis of MSCs to supernatants isolated from irradiated HuH7 
and MDA-MB-231 cells substantiating our hypothesis and formed the basis for an in 
vivo approach to improve the NIS-mediated iodide uptake in non-thyroidal tumors 
using MSCs as gene delivery vehicles by pretreating tumors with radiation. Previous 
studies demonstrated the excellent tumor-homing of MSCs into the microenvironment 
of different tumors [50-52, 57-60, 68]. The theranostic gene NIS is used for noninvasive 
imaging of functional NIS expression by 123I-scintigraphy, allowing efficient tracking of 
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NIS engineered MSCs in vivo by dynamic radioiodide imaging. We and others have 
extensively investigated the capacity of NIS to induce radioiodide accumulation in non-
thyroidal tumors using MSCs as NIS gene delivery vehicles [56-60]. The efficacy of 
MSCs to deliver the NIS gene deep into tumors has been shown in different 
approaches by our group [57-60]. Active MSC engraftment has been demonstrated in 
various tumor models, including subcutaneous and orthotopic HCC xenografts as well 
as a hepatic colon cancer metastases model [57-60]. These MSC-based NIS gene 
therapy approaches resulted in a significant delay in tumor growth and prolonged 
animal survival after radioiodine accumulation. We sought to build upon these results 
to improve the level and selectivity of MSC tumor homing, and to enhance the 
therapeutic efficacy of NIS-mediated 131I treatment to further increase selectivity, 
efficacy and safety. Using a previously described subcutaneous HCC mouse model 
and reporter MSCs engineered with a CMV-NIS construct, significantly increased MSC 
recruitment was demonstrated into tumor sites that had been irradiated with low-doses 
(2 and 5 Gy). Francois et al. demonstrated enhanced MSC migration after treatment 
of tumors with high doses (26.5 Gy) of radiation [63]. Studies of Zielske et al. showed 
that more MSCs migrated to tumors irradiated with a minimum of 5 Gy [69]. Different 
tumor types, including breast, colon and head/neck tumors, were irradiated with 2, 5 
or 9 Gy. Analysis of MSC recruitment showed enhanced recruitment in all tumors 
irradiated with 5 or 9 Gy, except in tumors established from UMSCC1 head/neck 
carcinoma cells [69]. On the other hand, Klopp et al. were able to efficiently attract 
MSCs to tumor sites of breast cancer using low-dose irradiation such as 1 and 2 Gy 
[65].  
We examined if MSC recruitment is enhanced in tumors pretreated with low-dose 
irradiation (2 or 5 Gy) using NIS imaging (123I-scintigraphy). Tumor-specific radioiodide 
uptake activity was observed in all groups (0, 2 and 5 Gy). Tumors locally treated with 
radiation revealed a significantly higher NIS-mediated iodide uptake after a single MSC 
application 24 h post radiation treatment compared to non-irradiated tumors. The 
maximum radioiodide uptake activity of tumors irradiated with 2 or 5 Gy was 7.9 and 
9.2 % ID/g respectively, whereas nonirradiated tumors accumulated only 5.3 % ID/g. 
The enhanced recruitment of MSCs into irradiated HuH7 tumors was also verified ex 
vivo using NIS immunohistochemistry that showed increased recruitment of NIS-MSCs 
in tumors pretreated with low-dose radiation.  
Importantly, the positive effects seen with low-dose irradiation (with lower toxicity and 
  Chapter 3 
 
81 
 
side effects on the normal surrounding tissues) effectively sets the stage for more 
detailed studies of the combined effects of enhanced delivery of therapy genes by 
MSCs with cancer radiation treatment. Radiotherapy has been also shown to have 
effects on the tumor stroma, which is comprised of tumor endothelial cells and cancer-
associated fibroblasts (CAFs) as well as other cell types [121]. Radiation of tumors not 
only leads to enhanced stimulation of cytokine and growth factor secretion by tumor 
cells but is also responsible for radiation-induced dysfunction or even apoptosis of 
tumor endothelial cells, which in turn lead to hypoxia, increased permeability as well 
as an enhanced inflammatory response [121, 122]. Due to vascular depletion, the pro-
angiogenic and pro-vasculogenic factors VEGF and CXCL12/SDF-1 are increased 
[121, 123, 124]. Radiation also drives activation of CAFs within the tumor stroma, which 
in turn increase growth factor secretion and the release of cytokines such as HGF, 
PDGF, CXCL12/SDF-1 and TGF𝛽 [121]. Another aspect besides an increased 
inflammatory response, which was shown in this study to increase MSC recruitment in 
vitro, is a possible radiation-induced stimulation of tumor vascular permeability, which 
could be another important trigger for enhanced MSC recruitment in vivo. Using doses 
of 5-10 Gy, an initial increase of tumor blood flow after irradiation has been reported 
with a return to levels seen before irradiation 2-3 days post radiation [125]. Taking this 
into consideration, irradiation-induced enhanced MSC migration to tumors might be a 
combinatorial effect of stimulated secretion of cytokines and growth factors involved in 
the process of MSC tumor homing as well as increased tumor permeability allowing 
MSCs to passage the tumor stroma more easily. These complex effects of irradiation 
on tumor cells and their (micro-)environment not only enhances MSC tumor 
recruitment as demonstrated in our study, but may also foster MSC tumor engraftment 
and therefore, represents a highly promising tool to significantly stimulate MSC-driven 
gene therapy approaches. Taken together, our results show a dose-dependent 
increase of NIS-mediated accumulation of 123I due to enhanced MSC recruitment to 
irradiated tumors using low-dose irradiation. Based on these findings an enhanced 
accumulation of the therapeutically active radioisotope 131I is expected after combining 
EBRT and MSC gene delivery, which we will evaluate in future studies.  
In summary, our study demonstrates that radiation of experimental HCC enhances the 
secretion of diverse inflammatory cytokines and growth factors involved in MSC 
migration, which can be linked to enhanced migration of adoptively applied MSCs deep 
into tumor microenvironments. These data open the exciting prospect for a new 
  Chapter 3 
 
82 
 
therapy approach, in which HCC tumors are pretreated with low-dose radiation prior to 
systemic MSC application aiming at increasing the efficacy of MSC-mediated NIS gene 
therapy.  
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5.6 Supporting Information 
5.6.1 Supplemental figures and tables 
 
 
Supplementary Fig. 1: Irradiation of MDA-MB-231 cells using 2, 5 or 10 Gy enhances gene expression 
of inflammatory cytokines and growth factors during a period of 8 to 48 h (A-D). Data are represented 
as mean fold change ± SEM as compared to nonirradiated MDA-MB-231 cells (n=3; two-tailed Student’s 
t-test: *P<0.05; **P<0.01, ***P<0.001).  
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Supplementary Fig. 2: MSCs subjected to a gradient of isolated supernatants from nonirradiated and 
irradiated MDA-MB-231 cells (2, 5 or 10 Gy) showed increased migration over 24 h (C-E, F-H) as 
compared to supernatants of untreated cells as controls, where only random chemokinesis was 
observed (A, B, F-H). One representative image each is shown from two independent experiments. 
Quantification of chemotaxis parameters as yFMI, yCoM and directionality was done (F-H). CoM is 
indicated by red dots (G). Data are represented as mean fold change ± SEM from two independent 
experiments. 
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6.1 Abstract 
 
The sodium iodide symporter (NIS) is the operational molecule that has allowed the 
efficient treatment of thyroid malignancies by the administration of 131I for over 70 
years. Various vector-driven approaches are currently under investigation to introduce 
the NIS gene into non-thyroidal tumors in order to more broadly apply this effective 
anticancer therapy. One such system makes use of genetically engineered 
mesenchymal stem cells (MSC) as therapy vehicles for the delivery of NIS into solid 
tumors. MSCs show an innate ability to home to and invade tumor environments in 
response to the danger signals and inflammatory cytokines produced by the tumor 
milieu. We and others have demonstrated that tissue or signal-specific gene promoters 
are able to enhance the specificity of MSC-mediated NIS transgene expression in 
tumors. External beam radiation therapy (EBRT), a standard principal therapeutic 
modality for the treatment of cancer, results in tissue damage and hence enhanced 
recruitment of NIS-expressing MSCs into human hepatocellular carcinoma (HuH7). At 
the same time, the tumor-associated cytokine TGFB1 is strongly upregulated in HuH7 
tumors in response to radiation pretreatment. In the current study, we show that 
combining EBRT with MSC-based NIS-mediated 131I therapy dramatically enhances 
therapeutic efficacy when a synthetic TGFB1-inducible SMAD-responsive promoter, 
as opposed to a constitutive CMV-promoter, is used to drive NIS expression in MSCs. 
It is thought that the remarkable therapeutic effect seen is linked to the enhanced 
TGFB1 produced in this context, which leads to a highly selective and focused 
amplification of MSC-based NIS expression within the tumor milieu. 
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6.2 Introduction 
 
The sodium iodide symporter (NIS) is an intrinsic transmembrane glycoprotein that 
actively transports iodide into the thyroid gland. NIS biology forms the basis for the 
efficient management of thyroid cancer patients through the use of radioiodine. NIS 
functions as a theranostic protein, allowing noninvasive imaging, such as 123I-
scintipgraphy and 124I-PET imaging, as well as treatment by application of therapeutic 
radioiodine (131I) [20, 21, 23, 126]. Diverse approaches are currently underway to 
investigate NIS-based therapy in non-thyroidal tumors using various delivery systems 
[20-23, 28, 30, 33, 34, 36-38, 41, 57-60]. Mesenchymal stem cells (MSCs) are 
attractive vehicles for the potential delivery of therapeutic genes into solid tumors. 
Adoptively applied, engineered versions of MSCs have been shown to allow the 
expression of therapeutic genes such as the NIS transgene deep within tumor 
environments [58-60]. The ability of MSCs to be recruited to tumor environments is due 
in large part to the release of various factors produced in response to the inflammation 
and hypoxic damage found in solid tumors [45-47]. The basic mechanisms underlying 
this recruitment are thought to parallel those seen in the recruitment of endogenous 
MSCs during tissue repair [45, 46].  
While radiation in general represents one of the most common therapies for the 
treatment of carcinoma patients, external beam radiation therapy (EBRT) now allows 
an accurate delivery of radiation to tumors that effectively limits damage to the 
surrounding normal tissue [127]. EBRT can be combined with other therapeutic 
approaches to refine or enhance tumor targeting and patient outcome. Recent studies 
have shown that radiation pretreatment of tumors can enhance the tumor-homing 
properties of adoptively applied MSCs [63, 65, 69, 128]. Tumor irradiation leads to an 
increased inflammatory response and an enhanced secretion of factors involved in 
MSC recruitment [47, 65, 129].  
Klopp et al. described enhanced MSC recruitment to irradiated murine mammary 
carcinoma [65]. A similar effect was also observed in irradiated gliomas using 
hematopoietic progenitor cells (HPC) [118]. Further, in a recent study our own group 
demonstrated enhanced secretion of various inflammatory factors involved in MSC 
tumor homing after irradiation of the human hepatocellular carcinoma (HCC) cell line 
HuH7. The increased expression of the chemokine (C-X-C motif) ligand 12/stromal 
cell-derived factor 1 (CXCL12/SDF-1), CXCL8, fibroblast growth factor 2 (FGF2), 
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platelet-derived growth factor (PDGF), transforming growth factor beta 1 (TGFB1), 
thrombospondin 1 (TSP-1) and vascular endothelial growth factor (VEGF) were linked 
to the enhanced migration of genetically engineered MSCs to the tumor stroma that in 
turn led to an increased expression of the theranostic NIS transgene under control of 
the constitutively active CMV-promoter [129]. Therefore, using radiation pretreatment 
to enhance the MSC tumor homing capability opens the exciting prospect of combining 
EBRT with MSC-mediated gene delivery strategies to improve transgene delivery to 
tumor environments.  
Our group has previously shown that the use of tissue or signal-specific gene 
promoters, whose activation is linked to tumor-derived signals, allow a more selective 
activation of MSC-based transgenes such as NIS and thereby can improve the 
specificity of tumor treatment [58-60, 128]. As TGFB plays important roles in the 
biology of tumor growth and is expressed by most solid tumors, a synthetic TGFB1-
inducible SMAD-responsive promoter, was tested in stably transfected engineered 
MSCs to control NIS transgene expression (SMAD-NIS-MSCs) within tumors. In our 
recent work we have reported that systemic application of SMAD-NIS-MSCs to mice 
harboring subcutaneous human hepatocellular carcinoma derived from the TGFB1-
expressing HuH7 cell line resulted in a significant delay in tumor growth and prolonged 
survival of animals [128]. This proof-of-principle of using the TGFB1-inducible SMAD-
responsive promoter as a tumor signal-responsive promoter in the setting of NIS gene 
therapy, together with the data from our previous work demonstrating stimulation of 
MSC recruitment by EBRT tumor pretreatment as well as identifying TGFB1 as a major 
tumor derived signals in response to EBRT treatment, suggested that EBRT may not 
only enhance the migratory behavior of MSCs but may also act to amplify promoter 
activation in SMAD-NIS-MSCs due to increased TGFB1 expression in irradiated 
tumors [128, 129]. We and others had previously speculated that gene promoters that 
are either directly or indirectly responsive to radiation-induced signals could potentially 
allow an amplification of therapy transgene expression when used in the setting of NIS-
mediated radioiodine therapy. The accumulated radioiodine-induced tumor damage in 
association with an inflammatory response that effectively drives the activation of the 
radiation-responsive promoter could lead to more efficient NIS expression. Based on 
this hypothesis and the data described above, we combined in the present study EBRT 
treatment with MSC-mediated SMAD-promoter-driven NIS gene transfer to evaluate 
potential additive effects. The therapeutic efficacy of engineered MSCs was tested by 
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combining radiation pretreatment of tumors with the application of either SMAD- or 
CMV-NIS-MSC-mediated NIS gene delivery in mice harboring subcutaneous HuH7 
tumors. MSCs were systemically injected 24 h after low-dose radiation pretreatment of 
the tumors. The subsequent effects on the tumoral TGFB1-induced, NIS-mediated 
radioiodide accumulation were examined using 123I-scintigraphy. Therapeutic efficacy 
was then determined after pretreating tumors with radiation followed by SMAD- or 
CMV-NIS-MSC-mediated NIS transgene delivery and 131I application. Pretreatment 
with low-dose external beam radiation of subcutaneous human HuH7 tumors, following 
systemic application of SMAD-NIS-MSCs resulted in an amazing reduction of tumor 
growth up to complete remission of tumors in a subset of animals and dramatically 
prolonged survival of animals as compared to animals receiving CMV-NIS-MSC 
treatment or controls. 
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6.3  Materials and methods  
 
Cell culture 
The human hepatocellular carcinoma cell line HuH7 used in the experiments were 
authenticated and purchased from JCRB Cell Bank (JCRB 0403, Osaka, Japan). 
DMEM (Sigma-Aldrich, St. Louis, Missouri, USA) supplemented with 10% FBS (FBS 
Superior, Biochrom/Merck Millipore, Berlin, Germany) and 100 U/ml penicillin/100 
µg/ml streptomycin (Sigma-Aldrich) was used for cell culture. The human bone marrow 
derived, SV40 large T antigen immortalized MSC cell line was described and cultured 
as described previously [111]. An incubator at 37°C and 5% CO2 was used for all cells. 
 
SMAD-NIS-MSCs  
The design of the pcDNA6-2ITRNEO-SMAD-NIS expression vector as well as the 
stable transfection of MSCs was performed as described previously [128]. SMAD-NIS-
MSCs were cultured in RPMI medium containing 0.5 mg/ml geneticin (Invitrogen), 10% 
fetal bovine serum and 100 U/ml penicillin/100 µg/ml streptomycin.  
125I uptake assay 
After starving cells overnight, SMAD-NIS-MSCs were stimulated with either only 10 
ng/ml recombinant TGFB1 or in combination with HuH7-CM (irradiated or 
nonirradiated) or HuH7-CM only for a period of 24 h to validate promoter inducibility. 
NIS-mediated radioiodide uptake of SMAD-NIS-MSC was determined at steady-state 
conditions as described previously [66]. Results were normalized to cell viability. 
 
Cell viability assay 
Cell viability was determined using the commercially available MTT assay (Sigma-
Aldrich) according to the manufacturer’s recommendations as described previously 
[60].  
 
Irradiation of HuH7 cells  
Irradiation of HuH7 cells using 5 Gy was performed as described previously [129]. 
Supernatants of irradiated and non-irradiated HuH7 cells were removed 48 h after 
irradiation, centrifuged and stored at -80°C.   
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Immunohistochemical TGFB1 staining 
Immunohistochemical TGFB1 staining were conducted as described previously [128]. 
 
Animals 
5-week-old female CD1 nu/nu mice were purchased from Charles River (Sulzfeld, 
Germany) and housed under specific pathogen-free conditions. Mice had access to 
mouse chow and water ad libitum. Experiments were approved by the regional 
governmental commission for animals (Regierung von Oberbayern) and performed in 
accordance with institutional guidelines of the Klinikum rechts der Isar, Technische 
Universität München. 
 
Establishment of HuH7 xenograft tumors 
To establish HuH7 xenograft tumors in CD1 nu/nu mice, 5 × 106 HuH7 cells/100 µl PBS 
were injected subcutaneously into the right flank region as described previously [57]. 
Regular measurment and estimation of the tumor volume were done using the 
equation: length × width × height × 0.52. Exceeding a tumor size of 1500 mm3 led to 
scarification of mice. 
 
Irradiation of HuH7 xenograft tumors 
The precise irradiation using 5 Gy was performed as described previously [129] after 
subcutaneous HuH7 tumors reached a diameter of approximately 5-10 mm for 123I-
scintigraphy or 1-5 mm for therapy.  
 
Systemic SMAD-NIS-MSC application and in vivo 123I-scintigraphy  
5 mg/ml L-T4 (Sigma-Aldrich) was supplemented to the drinking water of mice to 
suppress thyroidal iodide uptake. 24 h after tumor irradiation 5 × 105 SMAD-NIS-MSCs 
in 500µl PBS were systemically applied. 72 h after SMAD-NIS-MSC injection, 18.5 
MBq (0.5 mCi) of 123I were applied peritoneally. Radioiodide biodistribution was 
assessed using 123I-scintigraphy, a gamma camera provided with a low-energy high 
resolution collimator (e.cam, Siemens, Munich, Germany). Analysis of regions of 
interests (ROIs) was done with the HERMES GOLD (Hermes Medical Solutions, 
Stockholm, Sweden) program. Quantified results were expressed as a fraction of the 
total amount of applied radionuclide per gram tumor tissue (% ID/g). The radionuclide 
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retention time was determined by serial scanning within the tumors and dosimetric 
calculations were done as described previously [60].  
 
Immunohistochemical stainings for NIS expression  
After in vivo application of SMAD-NIS-MSCs, tumors and nontarget organs (liver, lung 
and spleen) were dissected. Paraffin-embedded tissues were immunohistochemically 
stained for NIS expression as described previously [130].  
 
Radioiodine therapy study  
10-days before therapy start, mice received drinking water supplemented with 5 mg/ml 
L-T4. For therapy, tumors were irradiated (5 Gy) followed by a single SMAD-NIS-MSCs 
application 24 h later. 72 h after the SMAD-NIS-MSC injection mice received 55.5 MBq 
131I (n=7; 5 Gy + SMAD-NIS-MSCs + 131I). 24 h after 131I application, the treatment 
cycle of radiation pretreatment and MSC application was repeated. For therapy 
completion, a last cycle as described was done without radiation pretreatment of 
tumors. As controls, a subset of mice received NaCl instead of radioiodide (n=8; 
SMAD-NIS-MSCs+NaCl) or saline only after radiation treatment (n = 6; 5 Gy + NaCl). 
For exact evaluation of the therapeutic effect, a subset of mice received no radiation 
therapy and only saline applications (n = 7; NaCl + NaCl). To illustrate the improved 
therapeutic effect of SMAD-NIS-MSCs, CMV-NIS-MSCs were applied instead for 
therapy (n=6; 5 Gy + SMAD-NIS-MSCs + 131I). Tumor volume was measured regularly 
and mice were euthanized when a tumor volume of 1500 mm3 was exceeded. 
 
Indirect immunofluorescence assay 
Frozen tissue sections of tumors from the radioiodine therapy study were used for 
indirect immunofluorescence analysis of Ki67 (cellular proliferation) and CD31 (blood 
vessel density) as described previously [60]. The percentage of positive cells for Ki67 
and CD31-positive areas within the tumors was quantified by evaluation of 5 high-
power fields per tumor (n=3, 5 Gy + SMAD-NIS-MSCs + 131I; n=4, 5 Gy + CMV-NIS-
MSCs + 131I; n=6, 5 Gy + SMAD-NIS-MSCs + NaCl; n=5, 5 Gy + NaCl; n=7, NaCl + 
NaCl) using ImageJ software (NIH, Bethesda, MD). Results are presented as means 
± SEM. Statistical significance was calculated using students t-test. 
 
Statistical methods 
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Results are expressed as mean ± SEM or percentage and statistical significance was 
tested by two-tailed Student´s t-test or one-way ANOVA for tumor volumes and log-
rank test for survival plots for experiments. P values of < 0.05 were considered 
significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
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6.4 Results 
 
In vitro NIS-mediated radioiodide uptake in SMAD-NIS-MSCs   
To verify the selective response of SMAD-based synthetic gene promoter, SMAD-NIS-
MSCs were stimulated in vitro with TGFB1 (10 ng/ml), which led to a 5.4 fold increase 
in NIS-mediated radioiodide 125I accumulation (Fig. 1). No accumulation of 125I was 
observed above background levels without TGFB1 stimulation. To further characterize 
the potential activation of this transgene response to tumor-radiation signals, SMAD-
NIS-MSCs were additionally treated with irradiated and non-irradiated HuH7- CM. 
Whereas no accumulation of 125I was observed after subjecting MSCs to HuH7-CM 
only, treatment with HuH7-CM together with TGFB1 resulted in an significant increase 
of radioiodide uptake of approximately 59 % in MSCs as compared to stimulation with 
TGFB1 only (Fig. 1). Radioiodide uptake activity in SMAD-NIS-MSCs stimulated with 
HuH7-CM from 5 Gy irradiated HuH7 cells (SMAD-NIS-MSCs + 5 Gy treated HuH7-
CM) and TGFB1 resulted in an additional increase of about 12 % as compared to the 
stimulation with normal HuH7-CM and TGFB1 (Fig. 1). These findings corroborate with 
the analysis of a TGFB1 enzyme linked immunosorbent assay (ELISA), where no 
active but inactive TGFB1 protein was detected in HuH7-CM (data not shown). 
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Fig. 1: SMAD-NIS-MSCs stably expressing NIS under control of a SMAD-responsive promoter. Iodide 
uptake studies demosntrated a 5.4-fold high NIS-specific, perchlorate-sensitive 125I uptake in SMAD-
NIS-MSCs stimulated with TGFB1 (10 ng/ml) as compared to unstimulated cells, where no radioiodide 
uptake above background levels was observed. Combined treatment of SMAD-NIS-MSCs with TGFB1 
(10 ng/ml) and HuH7-CM led to further increased radioiodide uptake as compared to stimulated cells 
without HuH7-CM. This effect was even enhanced adding HuH7-CM from HuH7 cells, which were 
irradiated with 5 Gy. No radioiodide accumulation above background levels was observed treating 
SMAD-NIS MSCs with HuH7-CM (non-irradiated or irradiated) alone. Data are represented as means 
of three independent experiments ± SEM (n=3; two-tailed Student’s t-test: *p<0.05; ** p <0.01, *** p 
<0.001). 
 
TGFB1 expression in non-irradiated and irradiated HuH7 tumors 
TGFB1 protein expression in subcutaneous HuH7 tumors was analyzed using 
immunohistochemistry (Fig. 2). Moderate TGFB1 expression was detected within the 
stroma of non-irradiated HuH7 tumors (Fig. 2a). Irradiation of tumors using a low-dose 
of 5 Gy led to an increase in TGFB1 protein expression within the tumor stroma (Fig. 
2b). 
 
 
Fig. 2: Tumor-specific TGFB1 protein expression. Dissected tumors showed TGFB1 protein expression 
(brown) in non-irradiated tumors (a) and an increased expression in tumors irradiated with low-dose 
radiation (5 Gy) (b). One representative image at 20× magnification is shown each. 
In vivo 123I-Scintigraphy  
Nude mice with subcutaneous HCC xenograft tumors received a single SMAD-NIS-
MSCs (0.5 × 106) injection via the tail vein (i.v.) 72 h prior to 123I-scintigraphy (Fig. 3a, 
b). To monitor radioiodide biodistribution, 18.5 MBq 123I were administered 
intraperitoneally. Non-irradiated HuH7 tumors revealed a radioiodide accumulation of 
approximately 7.0 % ID/g tumor and a biological half-life of 3.9 h with a tumor absorbed 
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dose of 52.37 mGy/MBq 131I (Fig. 3a, e). The stomach, salivary and thyroid gland as 
well as the urinary bladder, due to renal excretion, showed endogenous NIS-mediated 
radioiodide uptake. To demonstrate NIS-specificity, radioiodide uptake was blocked 
upon treatment with perchlorate 30 min prior to the radioiodide administration in a 
subset of mice (Fig. 3b). A second group of mice received tumor radiation pretreatment 
using 5 Gy 24 h prior to the single SMAD-NIS-MSCs application (Fig. 3c, d). The 
precise radiation of the subcutaneous tumors led to an increased NIS-specific 
radioiodide accumulation of approximately 9.8 % ID/g tumor as compared to non-
irradiated tumors (7.0 % ID/g tumor) (Fig. 3a, e). A biological half-life of 3.0 h and a 
tumor absorbed dose of 56.72 mGy/MBq 131I was calculated for the irradiated HuH7 
tumors. Perchlorate treatment resulted in no accumulation of radioiodide in irradiated 
tumors (Fig. 3d).           
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Fig. 3: 123I-scintigraphy showed increased NIS-specific tumoral radioiodide uptake after radiation 
pretreatment of tumors. Subcutaneous HuH7 tumors were irradiated with 5 Gy. A single systemic 
injection of SMAD-NIS-MSCs 24 h after radiation pretreatment of tumors resulted in a maximum of 
approximately 9.8 % ID/g tumor as compared to non-irradiated tumors followed by SMAD-NIS-MSC 
injection (7.0 % ID/g tumor) (a, c). Tumoral radioiodide uptake was blocked upon treatment with the 
NIS-specific inhibitor perchlorate (b, d). Data are represented as mean values ± SEM. 
 
Ex vivo NIS protein expression in HuH7 tumors 
NIS-immunohistochemistry was performed on non-irradiated as well as irradiated 
tumors after application of SMAD-NIS-MSCs showing high NIS-specific 
immunoreactivity throughout the tumor stroma (Fig. 4a, e). NIS protein expression was 
shown to be increased in the tumors receiving radiation pretreatment confirming an 
enhanced recruitment and activation of SMAD-NIS-MSCs in irradiated tumors (Fig. 
4e). No NIS protein expression was detected in non-target organs such as liver, lung 
and spleen (Fig. 4b-d, f-h).  
 
Fig. 4: Tumor-specific NIS protein expression. After 123I-scintigraphy, tumors were dissected and stained 
for NIS protein expression in SMAD-NIS-MSCs demonstrating high NIS-specific immunoreactivity (red) 
after receiving SMAD-NIS-MSCs (a, e). Tumor radiation pretreatment (5 Gy) led to increased NIS protein 
expression, thus confirming enhanced tumor homing of NIS-expressing MSCs to irradiated tumors (a). 
No NIS protein expression was detected in non-target organs (b-d). One representative image at 20× 
magnification is shown each. 
In vivo Radioiodine therapy studies 
Therapeutic efficacy of the SMAD-NIS-MSC-based NIS-mediated 131I therapy was 
then evaluated by systemically applying SMAD-NIS-MSCs in mice with subcutaneous 
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HuH7 tumors, which were pretreated with 5 Gy (5 Gy + SMAD-NIS-MSCs + I-131) (Fig. 
5). As controls, mice received radiation pretreatment followed by saline only (5 Gy + 
NaCl) or SMAD-NIS-MSCs followed by saline applications (5 Gy + SMAD-NIS-MSCs 
+ NaCl). A further control group received saline only (NaCl + NaCl). To evaluate if there 
is an improved therapeutic effect due to the use of tumor signal-responsive promoter 
that is also activated by the response of radiation, a group of mice with irradiated 
tumors received MSCs stably transfected with the constitutive active CMV-promoter to 
control NIS transgene expression followed by radioiodine treatment (5 Gy + CMV-NIS-
MSCs + I-131). Mice receiving NaCl only showed exponential tumor growth and had 
to be sacrificed within 35 days (Fig. 5a, b).  
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Fig. 5: 131I therapy of subcutaneous HuH7 tumors led to a significant delay in tumor growth and improved 
survival. For an in vivo radionuclide therapy study, mice received radiation pretreatment followed by a 
single SMAD-NIS-MSC application and 55.5 MBq 131I 48 h afterwards. This cycle was repeated, followed 
by a final cycle of a single SMAD-NIS-MSC application and 131I (5 Gy + SMAD-NIS-MSC + I-131) (a). 
Therapy of mice harboring HuH7 tumors resulted in a significant delay in tumor growth as compared to 
irradiated controls (5 Gy + NaCl (day 19-35, **p < 0.01) and 5 Gy + SMAD-NIS-MSC + NaCl (day 25-
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38, **p < 0.01 and day 39-49, *p < 0.05)) or mice receiving NaCl only (NaCl + NaCl (day 2-17, ***p < 
0.001 and day 18-21, **p < 0.01)) (a). Another therapy group received CMV-NIS-MSCs instead of 
SMAD-NIS-MSCs (5 Gy + CMV-NIS-MSCs + I-131) to evaluate the therapeutic efficacy of the tumor 
signal-responsive promoter. Both therapy groups demonstrated halted tumor growth at first, but CMV-
NIS-treated mice developed fast tumor progression after 20 days with nearly no difference in tumor 
growth as compared to irradiated controls (a). Therapy using radiation treatment in combination with 
SMAD-NIS-MSCs illustrated only slow tumor progression including two mice with complete tumor 
regression. Further, therapy mice (5 Gy + SMAD-NIS-MSC + I-131) demonstrated significantly improved 
overall survival after an observation period of 85 days as compared to all controls (b). 
Radiation pretreated tumors of control mice (5 Gy + NaCl and 5 Gy + SMAD-NIS-MSCs 
+ NaCl) led to significantly slower tumor growth as compared to the saline group (Fig. 
5a) and prolonged survival up to 69 days (Fig. 5b). The therapy mice (5 Gy + SMAD-
NIS-MSCs + I-131 and 5 Gy + CMV-NIS-MSCs + I-131) demonstrated significantly 
reduced tumor growth over that seen with radiation alone up to 20 days (Fig. 5a). After 
20 days, tumors of the 5 Gy + CMV-NIS-MSCs + I-131 group started growing and 
nearly no difference in tumor growth was observed as compared to irradiated control 
groups (Fig. 5a). By contrast, 5 Gy + SMAD-NIS-MSCs + I-131 mice showed 
dramatically slower tumor progression after 20 days (Fig. 5a). Two mice in this group 
showed complete tumor regression. Therapy mice (5 Gy + SMAD-NIS-MSCs + I-131) 
demonstrated significantly prolonged survival as compared to all controls (Fig. 5b). 
Survival of the therapy groups was recorded until day 85 and observation was still 
ongoing at the time of this report. At this stage, 4 of 7 SMAD-NIS-MSCs-treated therapy 
mice (5 Gy + SMAD-NIS-MSCs + I-131) are still alive (2 mice with no tumor and 2 mice 
with small tumors of about 150-500 mm3). By comparison, 1 of 6 mice from the CMV-
NIS-MSC therapy group was still alive at day 85. Dissected tumors were also stained 
for the proliferation marker Ki67 (green) and the blood vessel marker CD31 (red) using 
immunofluorescence analysis (Fig. 6). In this instance, no difference was seen 
between the therapy groups (5 Gy + SMAD-NIS-MSCs + I-131 and 5 Gy + CMV NIS-
MSCs + I-131) and mice of the controls (NaCl + NaCl, 5 Gy + NaCl or 5 Gy + SMAD-
NIS-MSCs + NaCl) (Fig 6a, b, c). 
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Fig. 6: Immunofluorescence staining of proliferating cells (Ki67) and blood vessels (CD31). 
Immunofluorescence analysis for Ki67 (green) and CD31 (red) showed no difference in proliferation as 
well as blood vessel density in resected tumors of mice treated with radiation and SMAD-NIS-MSC 
followed by 131I treatment as compared to therapy mice receiving CMV-NIS-MSCs or irradiated tumors 
of mice injected with SMAD-NIS-MSCs and NaCl or non-irradiated tumors receiving NaCl only (a-c). 
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Slides of tumors were counterstained with Hoechst nuclear stain and one representative image is shown 
each (20× magnification) (a). 
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6.5 Discussion 
 
Mesenchymal stem cells (MSCs) represent a promising tool for the delivery of 
therapeutic genes into tumor environments based on their strong tumor homing 
properties. The mechanisms underlying MSC migration to the tumor are thought to be 
driven by the inflammatory response of the tumor [46]. Key mediators in this scenario 
include inflammatory chemokines and growth factors such as the epidermal growth 
factor (EGF), PDGF, VEGF, CXCL12/SDF-1 and TGFB1/3 among others, which have 
been shown to attract MSCs [5, 47]. Irradiation of tumors has been shown to lead to 
an enhanced inflammatory response resulting in increased secretion of growth factors 
and chemokines, which in turn is associated with enhanced recruitment of MSCs [64, 
65]. In a recent proof-of-principle study, our group has shown that recruitment of MSCs 
expressing NIS under control of the CMV-promoter was strongly enhanced towards 
subcutaneous HuH7 tumors after tumor pretreatment with low-dose radiation [129]. 
Radiation treatment (1-10 Gy) of HuH7 cells showed a dose-dependent increase in 
expression of CXCL8, CXCL12/SDF-1, FGF2, PDGFB, VEGF, TSP-1 as well as 
TGFB1 [129]. In addition, the combination of tumor radiation pretreatment and MSC-
mediated NIS transgene delivery was found to result in enhanced NIS-mediated tumor-
specific radioiodide accumulation as compared to non-irradiated tumors [129]. Besides 
the combination of a MSC-based NIS-mediated gene therapy approach with 
conventional therapies such as EBRT, a major focus of our group has been to evaluate 
the use of tumor-derived signal-specific promoters for NIS transgene activation to 
enhance tumor-specificity and variability regarding tumor heterogeneity. NIS driven by 
the RANTES/CCL5-promoter has been evaluated in various tumor mouse models and 
demonstrated improved survival of the animals as compared to the use of the 
unspecific CMV-promoter [57-59]. In a recent study we have shown that using tumor 
hypoxia for driving NIS transgene expression resulted in a prolonged survival of 
animals and a significant delay in tumor growth in an orthotopic HCC mouse model 
[60]. Our most recent approach of individually designed promoters, which become 
activated by signals of the tumor micromilieu, was the use of a TGFB1-inducible 
SMAD-responsive promoter [128]. In most HCC the pleiotropic factor TGFB1 is 
upregulated by different cells of the tumor stroma and tumor cells and is an important 
factor for tumor micromilieu-associated signaling [102, 107, 114]. The TGFB signaling 
pathway can be used to activate NIS transgene expression through the TGFB1-
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inducible SMAD-responsive promoter in MSCs (SMAD-NIS-MSCs), where it resulted 
in a robust tumor-specific therapy response [128]. In parallel, we have described 
radiation-enhanced MSC tumor (HuH7) homing as well as increased TGFB1 
expression in response to radiation [129]. Combining of enhancing MSC-mediated NIS 
gene delivery and amplifying TGFB1-inducible NIS expression by radiation 
pretreatment of tumors offers great potential to improve tumoral NIS-mediated 
radioiodide accumulation by taking advantage of these additive effects. In vitro, SMAD-
NIS-MSCs demonstrated a robust and significant radioiodine uptake activity upon 
TGFB1 stimulation, which was significantly enhanced upon concomitant treatment with 
conditioned medium from HuH7 cells. A further stimulating effect was seen when 
conditioned medium from radiation pretreated (5 Gy) HuH7 cells was used. Further, 
immunohistology showed that non-irradiated HuH7 tumors had moderate TGFB1 
protein expression throughout the tumor, whereas even low-dose irradiation (5 Gy) of 
HuH7 tumors led to increased TGFB1-specific immunoreactivity in tumors. These 
findings correlate with our recent data showing an enhanced and dose-dependent 
TGFB1 expression on mRNA as well as protein level in irradiated HuH7 cells in vitro 
[129]. Based on these results, SMAD-NIS-MSC biodistribution in irradiated 
subcutaneous HuH7 tumors was investigated in vivo using NIS as reporter gene. 
External beam radiation was used to enhance TGFB1 expression and thus increase 
promoter activation in SMAD-NIS-MSCs as well as to enhance their migratory 
potential. Tumors treated with 5 Gy radiation followed by a single application of SMAD-
NIS-MSCs showed enhanced tumor-selective, TGFB1-driven induction of NIS that was 
demonstrated by high radioiodide accumulation of approximately 9.8 % ID/g tumor as 
compared to non-irradiated tumors (7.0 % ID/g tumor) using 123I-scintigraphy. Parallel 
studies using the constitutively active CMV-promoter in combination with tumor 
irradiation revealed similar results with approximately 9.2 % ID/g tumor using 5 Gy and 
5.3 % ID/g tumor in non-irradiated tumors [129]. As a next step towards clinical 
application, the therapeutic efficacy of combining EBRT with MSC-based, NIS-
mediated radioiodine therapy was evaluated. Radiation pretreatment itself 
demonstrated therapeutic efficacy in control mice (5 Gy + NaCl; 5 Gy + SMAD-NIS-
MSCs + NaCl) as compared to the saline only group (NaCl + NaCl). External beam 
radiation therapy in combination with the biologically targeted, NIS-mediated therapy 
(5 Gy + SMAD-NIS-MSCs + I-131) illustrated a robust therapeutic effect. Therapy mice 
demonstrated a halt in tumor growth for 20-30 days with some tumors growing very 
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slowly afterwards. Tumors of two mice within this group showed complete remission 
after approximately 40-50 days with no regrowth within the observation period of 85 
days. The combination of external beam radiation therapy and SMAD-NIS-MSCs-
mediated, NIS-induced 131I therapy demonstrated significantly reduced tumor growth 
in therapy mice as well as significantly improved survival as compared to controls or 
therapy using CMV-NIS-MSCs, which at first demonstrated halted tumor growth for 3 
to 4 weeks but showed tumor growth afterwards. The therapeutic effect seen was 
dramatically improved as compared to a 131I therapy approach using SMAD-NIS-MSCs 
without radiation pretreatment as well as compared to all former studies of our group 
using MSCs as NIS transgene delivery vehicles [57-60, 128]. However, no difference 
was seen between the groups in staining proliferating cells (Ki67) or blood vessels 
(CD31). An explanation might be the time point at which tumors are resected and 
stained. The respective tumor is dissected and stained when the mouse had to be 
sacrificed, because the tumor has exceeded a critical volume. In the present study, 
mice from the therapy group as well as radiation control groups lived very long and the 
time between treatment and tumor resection may have been too long, allowing 
recovery of the tumors and rebuilding of the tumoral vasculature. To investigate the 
direct effects of therapy on the proliferative behavior of tumor cells and vascularization 
of the tumors, tumors will have to be resected and stained at earlier time points, which 
has to be addressed in future studies.  
A critical aspect in the differences seen between the SMAD- and CMV-NIS-MSCs 
therapy might be the different characteristics of promoter activation. As the CMV-
promoter is constitutively active, application of radioiodine effectively eliminates all 
MSCs present within the tumor environment that sufficiently express NIS. However, 
SMAD-NIS-MSCs upregulate NIS expression based on direct signaling from the 
TGFB-based tumor signal that they receive from the micromilieu and thus are at 
different stages of promoter activation and therefore NIS transgene expression at the 
time radioiodine is applied. So only a subset of SMAD-NIS-MSCs may become 
activated by TGFB1 while others remain inactivated, thus surviving the first therapy 
round. The SMAD-NIS-MSCs surviving the first 131I course are then available to be 
activated in the second round of EBRT or radioiodine application, leading to a situation 
where SMAD-NIS-MSCs might accumulate from round to round, thus leading to the 
dramatic therapeutic effect seen in this study. Radiation-inducible promoters are 
currently under investigation as a means to efficiently combine gene therapy with 
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radiation treatment. These promoters normally regulate gene expression as response 
to the stress seen during radiation treatment and contain what can be thought of as 
radio-responsive elements [131]. The TGFB1-inducible SMAD-responsive promoter 
used in the current study makes use of an inflammatory response induced through 
radiation treatment leading to enhanced promoter activation and thus can be seen as 
an indirect but powerful radiation-inducible promoter.  
 
 
Fig. 7: Activation cycle of SMAD-NIS-MSCs after radiation pretreatment and radioiodine therapy. 
Radiation pretreatment of tumors leads to an enhanced inflammatory response resulting in a strong 
increase of TGFB1 expression within the tumor environment. Due to this response, SMAD-NIS-MSCs 
show enhanced recruitment to the tumor stroma as well as increased NIS expression based on high 
TGFB1 levels. Radioiodine treatment then results in SMAD-NIS-MSCs-induced tumor cell destruction 
eliciting an inflammatory response by itself and thereby amplifying the downstream effects and leading 
to an even stronger effect than seen with radiation alone. The combination of repeated radiation 
pretreatment and SMAD-NIS-MSCs-mediated radioiodine therapy becomes a self-energizing cycle 
leading to the improved therapeutic efficacy of NIS-based gene therapy seen in this study. 
 
The radiation effect induced by application of radioiodine is also thought to enhance 
the inflammatory response. Thus, NIS-based radioiodine therapy could by itself lead 
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to enhanced MSC recruitment as well as increased activation of the TGFB1, and the 
subsequent TGFB1-induced SMAD-promoter activity in MSCs results in prolonged NIS 
transgene expression due to repeated EBRT and radioiodine applications eventually 
leading to a self-energizing therapy cycle (Fig. 7).  
Improved biologically-targeted and tumor-selective radioiodine accumulation 
demonstrated a dramatic therapeutic response by combining radiation pretreatment 
and NIS-mediated 131I therapy. The tremendous therapeutic effect of this novel 
combination is based on taking advantage of the more than additive effects of 
radiation-induced tumor signals and tumor signal-responsive promoter activation that 
allows a significant amplification of tumor signal-specific NIS transgene expression.  
The results presented here demonstrate the great potential of the TGFB1-inducible 
SMAD-responsive promoter to be used as a tumor-specific and radiation-inducible 
promoter in the context of NIS cancer gene therapy to both selectively control 
therapeutic transgene expression within the tumor environment and amplify 
therapeutic efficacy. These data provide exciting preclinical evidence and open the 
prospect of clinical translation of this highly promising combination therapy approach 
for highly effective TGFB1-inducible NIS cancer gene therapy taking advantage of the 
increased understanding of the tumor homing capacity of MSCs as one of the most 
promising and flexible systemic gene delivery approaches available to date. 
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7. Summary 
The use of the theranostic sodium iodide symporter (NIS) for image-guided radioiodine 
therapy in non-thyroidal tumors has been extensively investigated in various tumor 
mouse models. The proof-of-principle of using NIS as a novel reporter and therapy 
gene has been convincingly demonstrated using different strategies for NIS transgene 
delivery, including systemic gene transfer targeting tumor metastases. The focus 
hereby lies in a safe application of the vectors followed by efficient transduction of 
tumor cells with a maximum of tumor selectivity and a minimum of off-target toxicity.
  
Mesenchymal stem cells (MSCs) have been developed as potent tumor therapy gene 
transfer vehicles based on their excellent active recruitment to both solid tumors and 
metastases. MSC-based NIS-mediated radioiodide therapy approaches have shown 
promising results in different studies, including our own work. As a next generation in 
the development of this system, we sought to improve the general strategy by 
enhancing both tumor-specificity and therapeutic efficacy.   
In the course of this thesis, the potential for clinical translation of MSC-mediated NIS 
gene transfer was demonstrated by making use of an advanced clinically highly 
relevant tumor mouse model, by characterizing more selective tumor-associated gene 
promoters for driving transgene expression in engineered MSCs and finally, by 
combining NIS-mediated radioiodide therapy with external beam radiation therapy.  
The evaluation of MSC-mediated NIS transgene delivery using a clinically highly 
relevant genetically engineered mouse model of pancreatic ductal adenocarcinoma 
(PDAC) helped to demonstrate the prominent preclinical efficacy of the general 
approach. These mice develop genetically induced aggressive pancreatic tumors and 
are well characterized to reliably reflect the human disease and present an ideal 
preclinical model for the evaluation of novel therapy approaches. In this study, we 
investigated the general tumor homing properties and tumor specificity of murine 
MSCs transfected with NIS linked to the constitutively active cytomegalovirus (CMV) 
promoter (NIS-MSCs) as well as NIS-induced radioiodide accumulation in PDAC. NIS-
MSCs demonstrated high radioiodide uptake activity in vitro and imaging studies in 
vivo using 123I-scintigraphy and 124I-PET imaging revealed active MSC recruitment to 
tumor sites and a strong NIS-induced radioiodide accumulation specifically in PDAC. 
The approximate uptake of 16 % injected dose per gram tumor (ID/g) was significantly 
higher than that seen in earlier studies and supports the potential efficacy of MSCs as 
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gene delivery vehicles in more advanced tumor mouse models. The therapeutic 
potential was investigated by application of NIS-MSCs followed by 131I, which resulted 
in reduced tumor growth in therapy animals, which is highly significant considering the 
aggressiveness of the tumor model. Further, slightly reduced tumor growth was 
observed in tumors receiving NIS-MSCs and saline only. Immunohistochemical 
analysis demonstrated differences within the stroma of tumors containing NIS-MSCs 
as compared to tumors without MSCs. In this setting, the presence of NIS-MSCs led 
to an increased activation of fibroblasts and their proliferative behavior as well as to a 
reconstruction of collagen within the tumor stroma, suggesting that the presence of 
MSCs in PDAC influences the stromal compartment in an antitumor way. This study 
demonstrates the enormous potential of MSC-based NIS transgene delivery in PDAC 
to monitor tumoral radioiodine accumulation by radioiodine imaging using NIS as 
reporter gene as well as a NIS-mediated 131I-based therapy in PDAC.   
As a next step, a novel tumor signal-specific promoter was investigated for NIS 
transgene expression in human MSCs to enhance tumor specificity and targeting 
variability. As the cytokine TGFB is a major player in tumorigenesis and is 
overexpressed in most tumors, the effect of NIS expression controlled by a TGFB1-
inducible SMAD-responsive promoter (SMAD-NIS-MSCs) was evaluated. After in vitro 
establishment and characterization of SMAD-NIS-MSCs, which revealed high TGFB1 
dose-dependent induction of radioiodide uptake, the biodistribution of SMAD-NIS-
MSCs in vivo was determined by 123I-scintigraphy monitoring. SMAD-NIS-MSCs 
showed effective tumor homing and NIS activation resulting in high tumoral radioiodide 
uptake in subcutaneous HuH7 tumors. These findings were confirmed by NIS-
immunohistochemistry, which demonstrated tumor-specific NIS protein expression 
and no detection of NIS immunostaining in nontarget organs (liver, spleen, lung). 
Furthermore, SMAD-NIS-MSCs-mediated 131I therapy resulted in strongly reduced 
tumor growth and prolonged survival of therapy animals. Tumor growth reduction was 
further confirmed by immunofluorescence analysis of Ki67 and CD31 expression 
showing decreased proliferating tumor cells as well as reduced density of blood 
vessels in therapy-treated mice. These data established a novel and effective 
approach for tumor-specific NIS gene expression taking advantage of tumor-derived 
signals using MSCs as gene delivery vehicles. 
To study, if it would be possible to enhance the general tumor homing properties of 
MSCs, the effect of pretreating tumors with external beam radiation therapy (EBRT) 
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was investigated. Extensive in vitro analysis by qPCR and ELISA revealed a strong 
increase in the secretion of factors involved in MSC tumor recruitment after tumor cell 
irradiation. Radiation of the human hepatocellular carcinoma cell line HuH7 using 
increasing doses (0-10 Gy) and at increasing time points (0-48h) showed a largely 
dose-dependent increase in the steady state mRNA expression of CXCL8, CXCL12, 
FGF2, PDGFB, VEGF, THBS-1 as well as TGFB1 varying in dose response and time. 
These results were further confirmed for most of the factors on protein level. The 
functional consequences of this increased cytokine production on the directed 
migration of MSCs was evaluated using a live cell tracking migration assay used to 
track changes in MSC migration after exposure to supernatants from untreated and 
irradiated HuH7 cells. An increase in mean forward migration index (yFMI), mean 
center of mass (yCoM) and mean directionality showed an enhanced chemotactic 
behavior of MSCs in response to irradiated supernatants. Analysis of the human breast 
adenocarcinoma cell line (MDA-MB-231) revealed similar results after radiation 
treatment. For proof-of-principle in vivo, subcutaneous HuH7 xenograft tumors were 
pretreated with radiation (0, 2 or 5 Gy) followed by a single CMV-NIS-MSC (NIS under 
control of the CMV promoter) application prior to 123I-scintigraphy. 123I-scintigraphy 
demonstrated a dose-dependent increase in NIS-mediated tumoral radioiodide 
accumulation in the irradiated tumors, which was further confirmed by NIS 
immunohistochemistry. These results highlight the enormous potential of using 
radiation tumor pretreatment to enhance MSC-mediated NIS gene transfer to tumors, 
which may be a powerful tool to improve therapeutic efficacy.  
In the final project, taking advantage of the results of the two former studies, EBRT 
was combined with the SMAD-NIS-MSC-mediated therapy approach. This therapy 
strategy offered the possibility to apply radiation not only to improve MSC homing to 
tumors, but also to enhance promoter activation in SMAD-NIS-MSCs by stimulated 
release of TGFB1 due to radiation treatment of HuH7 cells. SMAD-NIS-MSCs 
demonstrated enhanced radioiodide uptake activity in vitro after stimulation with 
conditioned medium from irradiated HuH7 cells and TGFB1. Further, ex vivo analysis 
of HuH7 tumors using immunohistochemistry showed increased TGFB1 protein 
expression within the tumor stroma after radiation treatment as compared to 
nonirradiated tumors. Evaluation by 123I-scintigraphy revealed a strong and improved 
increase in radioiodide accumulation in subcutaneous HuH7 tumors after radiation 
pretreatment with 5 Gy followed by a single SMAD-NIS-MSC application. For therapy, 
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mice received cycles of tumor radiation pretreatment followed by SMAD-NIS-MSC and 
131I applications. Therapy mice demonstrated significantly reduced tumor growth up to 
complete remission in a subset of tumors and remarkably improved survival as 
compared to controls, which received radiation followed by SMAD-NIS-MSCs and 
saline applications, radiation and saline, or saline only as treatment. In addition, the 
therapeutic efficacy of NIS-mediated radioiodine therapy in combination with EBRT 
was directly compared in mice receiving SMAD-NIS-MSCs or CMV-NIS-MSCs. 
Systemic application of the tumor-specific SMAD-NIS-MSCs demonstrated vastly 
improved therapeutic efficacy in comparison to the strong constitutive CMV-promoter 
used to drive NIS expression. The characteristics of promoter activation may have 
played a critical role in the therapeutic success seen in this study. MSCs transfected 
with the constitutive active CMV-promoter are presumably eliminated with the first 
application of radioiodine as these MSCs strongly express NIS. In contrast to that, 
SMAD-NIS-MSCs depend on the TGFB1 present in the tumor and thus may not show 
promoter activation (and NIS expression) at the time 131I is applied. As a consequence, 
a subset of SMAD-NIS-MSCs not activated in the first therapy round survive, allowing 
further recruitment and accumulation of SMAD-NIS-MSCs in the tumor stroma from 
round to round leading to an an even more dramatic therapy effect in the following 
rounds. This may help explain the drastic therapeutic effect seen in SMAD-NIS-MSCs-
treated mice as compared to using CMV-NIS-MSCs. Another possibility is that 
radioiodine application leads to an enhanced inflammatory response within the tumor. 
This results in a self-energizing cycle of inflammatory response (enhancing MSC 
recruitment) and increasing TGFB1 production (leading to an activation of the SMAD-
promoter) following every round of EBRT and also NIS-mediated radioiodine therapy, 
resulting in the tremendous therapy effect seen. This hypothesis and the findings 
outlined above demonstrate the enormous potential and importance of using tumor-
stroma specific promoters for NIS transgene expression in MSCs. The TGFB1-
inducible SMAD-responsive promoter represents a powerful radiation-responsive 
promoter, activated by secondary events caused by radiotherapy.  
In conclusion, the studies performed in this thesis dramatically refined and improved 
the use of genetically engineered MSCs as tumor-specific NIS transgene delivery 
vehicles. The great potential of a MSC-driven, image-guided NIS-mediated radioiodine 
therapy was successfully demonstrated in an advanced genetically engineered mouse 
model of PDAC. This concept was further improved using a highly tumor-relevant gene 
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promoter targeting the TGFB signaling pathway as well as combining the MSC-based 
NIS gene therapy approach with radiation therapy, which demonstrated greatly 
enhanced therapeutic efficacy. Ultimately, the combination of EBRT, with its effects on 
improved MSC tumor homing and stimulation of tumoral TGFB1 release, and TGFB1-
inducible SMAD-NIS-MSCs tremendously improved the efficacy of the MSC-mediated 
NIS gene therapy approach including an amplification of MSC homing and SMAD-
promoter activation induced by an additional inflammatory response triggered in the 
tumor by NIS-delivered radioiodine. These data open the exciting prospect for clinical 
translation of MSC-mediated NIS gene radionuclide therapy for nonthyroidal tumors 
and their metastases, especially in combination with external beam radiation therapy.  
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